<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>건강과 대안 &#187; EU</title>
	<atom:link href="http://www.chsc.or.kr/tag/EU/feed" rel="self" type="application/rss+xml" />
	<link>http://www.chsc.or.kr</link>
	<description>연구공동체</description>
	<lastBuildDate>Mon, 13 Apr 2026 01:34:28 +0000</lastBuildDate>
	<language>ko-KR</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.5.2</generator>
		<item>
		<title>보고서: 대서양자유무역협정에 대한 초국적제약사의 희망사항이 유럽의 보건의료정책을 무력화시킬 것</title>
		<link>http://www.chsc.or.kr/?post_type=reference&#038;p=11677</link>
		<comments>http://www.chsc.or.kr/?post_type=reference&#038;p=11677#comments</comments>
		<pubDate>Tue, 25 Mar 2014 08:37:06 +0000</pubDate>
		<dc:creator>건강과대안</dc:creator>
				<category><![CDATA[공공의료]]></category>
		<category><![CDATA[보건의료제도]]></category>
		<category><![CDATA[자유무역협정(TPP, FTA)]]></category>
		<category><![CDATA[지적재산권·특허]]></category>
		<category><![CDATA[EU]]></category>
		<category><![CDATA[TTIP]]></category>
		<category><![CDATA[대서양자유무역협정]]></category>
		<category><![CDATA[미국]]></category>
		<category><![CDATA[신약]]></category>
		<category><![CDATA[의약품 특허]]></category>
		<category><![CDATA[임상시험]]></category>
		<category><![CDATA[지적재산권]]></category>
		<category><![CDATA[투자자국가중재]]></category>

		<guid isPermaLink="false">http://www.chsc.or.kr/?post_type=reference&#038;p=11677</guid>
		<description><![CDATA[*아래 내용은 &#60;주간 정보공유동향&#62;(2014. 3. 25. 정보공유연대 발간)에서 가져온 내용입니다. [ 보고서: 대서양자유무역협정에 대한 초국적제약사의 희망사항이 유럽의 보건의료정책을 무력화시킬 것 ]* 3월 24일 Health Action International Europe 등 [...]]]></description>
				<content:encoded><![CDATA[<p><span style="color: #0000ff;">*아래 내용은 &lt;주간 정보공유동향&gt;(2014. 3. 25. 정보공유연대 발간)에서 가져온 내용입니다. </span></p>
<p><strong>[ 보고서: 대서양자유무역협정에 대한 초국적제약사의 희망사항이 유럽의 보건의료정책을 무력화시킬 것 ]*</strong></p>
<p>3월 24일 Health Action International Europe 등 유럽의 6개 단체가 공동으로 대서양무역협정(TTIP 또는 TAFTA)에 대한 초국적제약사의 Wish List에 대한 분석 보고서를 발표했다. 대서양무역협정은 미국과 유럽연합간 협상중인 자유무역협정이다. 초국적제약사의 Wish List중 가장 우려스러운 5가지 제안을 다음과 같이 꼽았다.</p>
<p>① 지적재산권 규정의 변화: 독점기간 연장, 높은 약가, 치료적 가치가 나아지지 않은 신약의 증가</p>
<p>② 약가 및 상환정책 제한: 국가보건의료시스템내에서 약가를 통제하기위한 정부정책 무력화</p>
<p>③ 임상시험의 투명성 제한: 유럽의약품기구(EMA)의 임상시험에 대한 새로운 규정을 무력화</p>
<p>④ 분쟁메카니즘 등: 투자자국가중재(ISD), 정책결정에 기업의 개입 증가</p>
<p>⑤ 국제기준 변화: 다른 나라에도 부정적 영향을 미칠 것</p>
<p>이 중에서 지적재산권 규정에 대해서는 특허기간 연장, 허가-특허 연계, 특허적격성, 생물학적제제에 대한 자료독점권, 상표권이 의약품접근권 및 보건의료에 악영향을 미칠 것이라고 지적했다.  지적재산권 관련 법과 규정에 있어서 유럽과 미국간에는 상당한 차이가 있다. 유럽에는 의약품 시판허가과정에서 소요된 기간에 대해서는 특허기간을 연장해주고 있지만 특허심사 및 등록과정에서 소요된 기간에 대해서는 특허기간 연장을 허용하지 않고 있다. 그리고 유럽에서는 허가-특허 연계가 허용되지 않고, EU Directive 2001/83/EC와 배치된다. 유럽사법재판소는 허가-특허 연계제도를 반경쟁메카니즘으로 취급한다. 특허적격성 기준은 유럽이 미국보다는 엄격하다. 예를 들어 특허적격성 기준 중에서 유용성(utility, 미국)과 산업적 적용기준(industrial application standard, 유럽)은 비슷하게 취급되는데 일반적으로 유용성이 더 낮은, 느슨한 기준이다. 유럽이 자료독점권에 대해서는 강세이지만 미국이 생물학적제제(바이오의약품)에 대한 자료독점권을 12년 보장하고 있어서 이에 대해서도 우려한다. 또한 상표권을 제한하지 않으면 일반명, 성분명 사용을 제한받을 수 있다고 우려한다.</p>
<p>유럽은 국가보건의료체계가 잘 갖춰줘있는 편이지만 비싼 약값으로 인한 재정부담을 갖고 있다. 특히 포르투갈, 스페인, 그리스는 재정위기를 겪은 후 의약품지출을 상당히 줄였는데, 그리스의 경우 6천명이상의 어린이에게 백신접종을 못하고 있는 상황이다. 대서양자유무역협정에 대한 초국적제약회사의 희망사항이 받아들여진다면 이러한 상황은 더욱 악화될 것이라고 우려했다.</p>
<p>-보도자료 및 보고서:  The US-EU Trade Agreement Proposals by the pharmaceutical<br />
industry undermine European public policy making and public health<br />
&lt;<a href="http://commonsnetwork.eu/wp-content/uploads/2014/03/EN_Press-release-TTIP_Big-Pharma.pdf" target="_blank">http://commonsnetwork.eu/wp-<wbr></wbr>content/uploads/2014/03/EN_<wbr></wbr>Press-release-TTIP_Big-Pharma.<wbr></wbr>pdf</a>&gt;</p>
<p>*원문 보고서는 아래 링크에 가면 볼 수 있습니다.</p>
<p><a href="http://commonsnetwork.eu/wp-content/uploads/2014/03/24_03_2014_CivilSocietyResponse_BigPharma_WishList_final1.pdf">http://commonsnetwork.eu/wp-content/uploads/2014/03/24_03_2014_CivilSocietyResponse_BigPharma_WishList_final1.pdf</a></p>
]]></content:encoded>
			<wfw:commentRss>http://www.chsc.or.kr/?post_type=reference&#038;p=11677/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>[줄기세포] EU, 재생의학과 줄기세포과학의 현황 및 전망</title>
		<link>http://www.chsc.or.kr/?post_type=reference&#038;p=4074</link>
		<comments>http://www.chsc.or.kr/?post_type=reference&#038;p=4074#comments</comments>
		<pubDate>Mon, 27 May 2013 19:32:24 +0000</pubDate>
		<dc:creator>건강과대안</dc:creator>
				<category><![CDATA[과학기술 · 생의학]]></category>
		<category><![CDATA[줄기세포]]></category>
		<category><![CDATA[EU]]></category>
		<category><![CDATA[Stem cells]]></category>
		<category><![CDATA[분화세포(specialised cells)]]></category>
		<category><![CDATA[재생의학(regenerative medicines)]]></category>
		<category><![CDATA[특허성(patentability)]]></category>

		<guid isPermaLink="false">http://www.chsc.or.kr/?post_type=reference&#038;p=4074</guid>
		<description><![CDATA[EU, 재생의학과 줄기세포과학의 현황 및 전망http://www.now.go.kr/service/policy/foreign/view.jsp□ 목적 ○ 이 보고서는 줄기세포 과학을 조사하고, 아시아와 그 외 지역 국가들의 규제 및 발전 현황을 제공하며, 유럽과 미국의 현황을 비교함 - [...]]]></description>
				<content:encoded><![CDATA[<p><P class=MsoNormal style="MARGIN: 0cm 0cm 0pt"><B style="mso-bidi-font-weight: normal"><SPAN style="FONT-FAMILY: 굴림; mso-bidi-font-size: 10.0pt"><FONT size=2>EU, 재생의학과 줄기세포과학의 현황 및 전망<BR><BR><A href="http://www.now.go.kr/service/policy/foreign/view.jsp">http://www.now.go.kr/service/policy/foreign/view.jsp</A><BR><BR>□ 목적<SPAN lang=EN-US><?XML:NAMESPACE PREFIX = O /><O:P></O:P></SPAN></FONT></SPAN></B></P><BR><br />
<P class=MsoNormal style="MARGIN: 0cm 0cm 0pt"><SPAN style="FONT-FAMILY: 굴림; mso-bidi-font-size: 10.0pt"><FONT size=2>○ 이 보고서는 줄기세포 과학을 조사하고<SPAN lang=EN-US>, </SPAN>아시아와 그 외 지역 국가들의 규제 및 발전 현황을 제공하며<SPAN lang=EN-US>, </SPAN>유럽과 미국의 현황을 비교함<SPAN lang=EN-US><O:P></O:P></SPAN></FONT></SPAN></P><BR><br />
<P class=MsoNormal style="MARGIN: 0cm 0cm 0pt"><FONT size=2><SPAN lang=EN-US style="FONT-FAMILY: 굴림; mso-bidi-font-size: 10.0pt">- </SPAN><SPAN style="FONT-FAMILY: 굴림; mso-bidi-font-size: 10.0pt">이 보고서는 재생의학<SPAN lang=EN-US>(</SPAN></SPAN><SPAN lang=EN-US style="COLOR: black; FONT-FAMILY: 굴림; mso-bidi-font-size: 10.0pt; mso-bidi-font-family: 'ITC Officina Serif Std Book'">regenerative medicines)</SPAN><SPAN lang=EN-US style="FONT-FAMILY: 굴림; mso-bidi-font-size: 10.0pt"> </SPAN><SPAN style="FONT-FAMILY: 굴림; mso-bidi-font-size: 10.0pt">및 줄기세포에 관한 과학<SPAN lang=EN-US>, </SPAN>정책<SPAN lang=EN-US>, </SPAN>규제<SPAN lang=EN-US>, </SPAN>자금지원<SPAN lang=EN-US>, </SPAN>윤리<SPAN lang=EN-US>, </SPAN>중개연구<SPAN lang=EN-US>, </SPAN>상업화 분야 전문가들의 견해를 제시함으로써<SPAN lang=EN-US>, </SPAN>유럽의 강력한 연구<SPAN lang=EN-US>/</SPAN>임상 기반을 이용하는데 필요한 활동이 무엇인지를 파악하고<SPAN lang=EN-US>, </SPAN>특허성<SPAN lang=EN-US>(</SPAN></SPAN><SPAN lang=EN-US style="COLOR: black; FONT-FAMILY: 굴림; mso-bidi-font-size: 10.0pt; mso-bidi-font-family: 'ITC Officina Serif Std Book'">patentability)</SPAN><SPAN lang=EN-US style="FONT-FAMILY: 굴림; mso-bidi-font-size: 10.0pt"> </SPAN><SPAN style="FONT-FAMILY: 굴림; mso-bidi-font-size: 10.0pt">제한에 의해 발생할 수 있는 결과를 조사하며<SPAN lang=EN-US>, </SPAN>자금지원 규칙의 변화가 미칠 수 있는 영향을 검토함 <SPAN lang=EN-US><O:P></O:P></SPAN></SPAN></FONT></P><BR><br />
<P class=MsoNormal style="MARGIN: 0cm 0cm 0pt"><SPAN lang=EN-US style="FONT-FAMILY: 굴림; mso-bidi-font-size: 10.0pt"><O:P><FONT size=2>&nbsp;</FONT></O:P></SPAN></P><BR><br />
<P class=MsoNormal style="MARGIN: 0cm 0cm 0pt"><B style="mso-bidi-font-weight: normal"><SPAN style="FONT-FAMILY: 굴림; mso-bidi-font-size: 10.0pt"><FONT size=2>□ 주요 결론<SPAN lang=EN-US><O:P></O:P></SPAN></FONT></SPAN></B></P><BR><br />
<P class=MsoNormal style="MARGIN: 0cm 0cm 0pt"><SPAN style="FONT-FAMILY: 굴림; mso-bidi-font-size: 10.0pt"><FONT size=2>○ 인간배아 줄기세포 연구의 축소는 전체적으로 재생의학과 세포치료를 저해할 것임<SPAN lang=EN-US><O:P></O:P></SPAN></FONT></SPAN></P><BR><br />
<P class=MsoNormal style="MARGIN: 0cm 0cm 0pt"><FONT size=2><SPAN lang=EN-US style="FONT-FAMILY: 굴림; mso-bidi-font-size: 10.0pt">- </SPAN><SPAN style="FONT-FAMILY: 굴림; mso-bidi-font-size: 10.0pt">핵심 기초과학을 약화시키고<SPAN lang=EN-US>, </SPAN>다학문적 분야에 중요한 협력을 방해하며<SPAN lang=EN-US>, </SPAN>투자자들에게 잘못된 메시지를 전달하고<SPAN lang=EN-US>, </SPAN>유럽의 혁신을 손상시킴<SPAN lang=EN-US><O:P></O:P></SPAN></SPAN></FONT></P><BR><br />
<P class=MsoNormal style="MARGIN: 0cm 0cm 0pt"><SPAN lang=EN-US style="FONT-FAMILY: 굴림; mso-bidi-font-size: 10.0pt"><O:P><FONT size=2>&nbsp;</FONT></O:P></SPAN></P><BR><br />
<P class=MsoNormal style="MARGIN: 0cm 0cm 0pt"><FONT size=2><SPAN style="FONT-FAMILY: 굴림; mso-bidi-font-size: 10.0pt">○ 성체세포를 리프로그래밍<SPAN lang=EN-US>(</SPAN></SPAN><SPAN lang=EN-US style="COLOR: black; FONT-FAMILY: 굴림; mso-bidi-font-size: 10.0pt; mso-bidi-font-family: 'ITC Officina Serif Std Book'">reprogramming)</SPAN><SPAN style="COLOR: black; FONT-FAMILY: 굴림; mso-bidi-font-size: 10.0pt; mso-bidi-font-family: 'ITC Officina Serif Std Book'">하여 얻어진</SPAN><SPAN style="FONT-FAMILY: 굴림; mso-bidi-font-size: 10.0pt"> 유도만능줄기세포<SPAN lang=EN-US>(i</SPAN></SPAN><SPAN lang=EN-US style="COLOR: black; FONT-FAMILY: 굴림; mso-bidi-font-size: 10.0pt; mso-bidi-font-family: 'ITC Officina Serif Std Book'">nduced pluripotent stem cells)</SPAN><SPAN style="COLOR: black; FONT-FAMILY: 굴림; mso-bidi-font-size: 10.0pt; mso-bidi-font-family: 'ITC Officina Serif Std Book'">는 중요한 획기적인 발전이며<SPAN lang=EN-US>, </SPAN>의약품 발견과 질병연구 및 만능성<SPAN lang=EN-US>(pluripotency) </SPAN>연구를 위한 강력한 새로운 도구</SPAN><SPAN style="FONT-FAMILY: 굴림; mso-bidi-font-size: 10.0pt">이지만<SPAN lang=EN-US>, </SPAN>현재 세포치료법에 사용하는데 적합하지 않음 <SPAN lang=EN-US><O:P></O:P></SPAN></SPAN></FONT></P><BR><br />
<P class=MsoNormal style="MARGIN: 0cm 0cm 0pt"><SPAN lang=EN-US style="FONT-FAMILY: 굴림; mso-bidi-font-size: 10.0pt"><O:P><FONT size=2>&nbsp;</FONT></O:P></SPAN></P><BR><br />
<P class=MsoNormal style="MARGIN: 0cm 0cm 0pt"><FONT size=2><SPAN style="FONT-FAMILY: 굴림; mso-bidi-font-size: 10.0pt">○ 만능성의 <SPAN lang=EN-US>‘</SPAN>골드 스탠다드<SPAN lang=EN-US>(</SPAN></SPAN><SPAN lang=EN-US style="COLOR: black; FONT-FAMILY: 굴림; mso-bidi-font-size: 10.0pt; mso-bidi-font-family: 'ITC Officina Serif Std Book'">gold standard)’</SPAN><SPAN style="COLOR: black; FONT-FAMILY: 굴림; mso-bidi-font-size: 10.0pt; mso-bidi-font-family: 'ITC Officina Serif Std Book'">로서<SPAN lang=EN-US>, </SPAN>인간배아 </SPAN><SPAN style="FONT-FAMILY: 굴림; mso-bidi-font-size: 10.0pt">줄기세포는 정상적인 만능상태의 기준으로서<SPAN lang=EN-US>, </SPAN>그리고 줄기세포를 분화세포<SPAN lang=EN-US>(</SPAN></SPAN><SPAN lang=EN-US style="COLOR: black; FONT-FAMILY: 굴림; mso-bidi-font-size: 10.0pt; mso-bidi-font-family: 'ITC Officina Serif Std Book'">specialised cells</SPAN><SPAN lang=EN-US style="FONT-FAMILY: 굴림; mso-bidi-font-size: 10.0pt">)</SPAN><SPAN style="FONT-FAMILY: 굴림; mso-bidi-font-size: 10.0pt">로 만드는 메커니즘을 이해하는 기준으로서 필요함 <SPAN lang=EN-US><SPAN style="mso-spacerun: yes">&nbsp;&nbsp;&nbsp;</SPAN><O:P></O:P></SPAN></SPAN></FONT></P><BR><br />
<P class=MsoNormal style="MARGIN: 0cm 0cm 0pt"><SPAN lang=EN-US style="FONT-FAMILY: 굴림; mso-bidi-font-size: 10.0pt"><O:P><FONT size=2>&nbsp;</FONT></O:P></SPAN></P><BR><br />
<P class=MsoNormal style="MARGIN: 0cm 0cm 0pt"><FONT size=2><SPAN style="FONT-FAMILY: 굴림; mso-bidi-font-size: 10.0pt">○ <SPAN lang=EN-US>2011</SPAN>년<SPAN lang=EN-US> 11</SPAN>월<SPAN lang=EN-US> EU </SPAN>재판소<SPAN lang=EN-US>(</SPAN></SPAN><SPAN lang=EN-US style="COLOR: black; FONT-FAMILY: 굴림; mso-bidi-font-size: 10.0pt; mso-bidi-font-family: 'ITC Officina Serif Std Book'">Court of Justice of the European Union)</SPAN><SPAN style="FONT-FAMILY: 굴림; mso-bidi-font-size: 10.0pt">는 인간배아에서 유도된 세포치료법은 특허를 받을 수 없다는 판결을 내렸으나<SPAN lang=EN-US>, </SPAN>이 판결이 인간배아 줄기세포에 기초한 제품의 상업화를 막지는 않을 것임 <SPAN lang=EN-US><O:P></O:P></SPAN></SPAN></FONT></P><BR><br />
<P class=MsoNormal style="MARGIN: 0cm 0cm 0pt"><FONT size=2><SPAN lang=EN-US style="FONT-FAMILY: 굴림; mso-bidi-font-size: 10.0pt">- </SPAN><SPAN style="FONT-FAMILY: 굴림; mso-bidi-font-size: 10.0pt">현재 독일의 연방법원<SPAN lang=EN-US>(EU </SPAN>재판소에 소송을 제기함<SPAN lang=EN-US>)</SPAN>은 인간배아 줄기세포에 기초한 제품 개발이 배아의 파괴를 포함하지 않는 한 이 제품에 관한 특허를 승인할 수 있다는 판결을 내림<SPAN lang=EN-US><O:P></O:P></SPAN></SPAN></FONT></P><BR><br />
<P class=MsoNormal style="MARGIN: 0cm 0cm 0pt"><FONT size=2><SPAN lang=EN-US style="FONT-FAMILY: 굴림; mso-bidi-font-size: 10.0pt">- </SPAN><SPAN style="FONT-FAMILY: 굴림; mso-bidi-font-size: 10.0pt">어떤 경우든<SPAN lang=EN-US>, </SPAN>제품은 개발에 관련된 중요한 노하우<SPAN lang=EN-US>(</SPAN></SPAN><SPAN lang=EN-US style="COLOR: black; FONT-FAMILY: 굴림; mso-bidi-font-size: 10.0pt; mso-bidi-font-family: 'ITC Officina Serif Std Book'">know-how)</SPAN><SPAN style="COLOR: black; FONT-FAMILY: 굴림; mso-bidi-font-size: 10.0pt; mso-bidi-font-family: 'ITC Officina Serif Std Book'">에 의해<SPAN lang=EN-US>, </SPAN>그리고 전달시스템<SPAN lang=EN-US>(delivery system) </SPAN>및 제조공정과 같은 주변 기술의 특허에 의해 보호될 것임<SPAN lang=EN-US><O:P></O:P></SPAN></SPAN></FONT></P><BR><br />
<P class=MsoNormal style="MARGIN: 0cm 0cm 0pt"><FONT size=2><SPAN lang=EN-US style="COLOR: black; FONT-FAMILY: 굴림; mso-bidi-font-size: 10.0pt; mso-bidi-font-family: 'ITC Officina Serif Std Book'">- </SPAN><SPAN style="COLOR: black; FONT-FAMILY: 굴림; mso-bidi-font-size: 10.0pt; mso-bidi-font-family: 'ITC Officina Serif Std Book'">따라서<SPAN lang=EN-US>, </SPAN>상업적 잠재력을 이유로<SPAN lang=EN-US>, </SPAN>인간배아 줄기세포 연구가 호라이즌<SPAN lang=EN-US> 2020(Horizon 2020) </SPAN>하에 자금을 지원받아서는 안된다는 주장을 정당화할 수 없음<SPAN lang=EN-US><SPAN style="mso-spacerun: yes">&nbsp; </SPAN><SPAN style="mso-spacerun: yes">&nbsp;</SPAN></SPAN></SPAN><SPAN lang=EN-US style="FONT-FAMILY: 굴림; mso-bidi-font-size: 10.0pt"><SPAN style="mso-spacerun: yes">&nbsp;</SPAN><O:P></O:P></SPAN></FONT></P><BR><br />
<P class=MsoNormal style="MARGIN: 0cm 0cm 0pt"><SPAN lang=EN-US style="FONT-FAMILY: 굴림; mso-bidi-font-size: 10.0pt"><O:P><FONT size=2>&nbsp;</FONT></O:P></SPAN></P><BR><br />
<P class=MsoNormal style="MARGIN: 0cm 0cm 0pt"><SPAN style="FONT-FAMILY: 굴림; mso-bidi-font-size: 10.0pt"><FONT size=2>○ 인간배아 줄기세포 연구<SPAN lang=EN-US>(</SPAN>지금까지<SPAN lang=EN-US> 18</SPAN>개 프로젝트에<SPAN lang=EN-US> 1</SPAN>억<SPAN lang=EN-US> 700</SPAN>만 유로가 지원됨<SPAN lang=EN-US>)</SPAN>는 현재<SPAN lang=EN-US> EU R&#038;D </SPAN>프로그램에서 비록 작은 비율을 차지하지만<SPAN lang=EN-US>,&nbsp;</SPAN>제<SPAN lang=EN-US>7</SPAN>차 연구 프레임워크 프로그램<SPAN lang=EN-US>(FP7, 2007~2013)</SPAN>은 이 자금지원을 삭감함으로써 부정적인 영향을 발생시킬 것임<SPAN lang=EN-US><O:P></O:P></SPAN></FONT></SPAN></P><BR><br />
<P class=MsoNormal style="MARGIN: 0cm 0cm 0pt"><SPAN lang=EN-US style="FONT-FAMILY: 굴림; mso-bidi-font-size: 10.0pt"><O:P><FONT size=2>&nbsp;</FONT></O:P></SPAN></P><BR><br />
<P class=MsoNormal style="MARGIN: 0cm 0cm 0pt"><SPAN style="FONT-FAMILY: 굴림; mso-bidi-font-size: 10.0pt"><FONT size=2>○ 세포치료는 현실화되었지만<SPAN lang=EN-US>, </SPAN>그 이점을 완전히 제공하기 위해서는 적합한 규제 하의 임상시험에 의한 증거가 있어야 함<SPAN lang=EN-US><O:P></O:P></SPAN></FONT></SPAN></P><BR><br />
<P class=MsoNormal style="MARGIN: 0cm 0cm 0pt"><FONT size=2><SPAN lang=EN-US style="FONT-FAMILY: 굴림; mso-bidi-font-size: 10.0pt">- </SPAN><SPAN style="FONT-FAMILY: 굴림; mso-bidi-font-size: 10.0pt">이를 통해<SPAN lang=EN-US>, </SPAN>새로운 형태의 의학으로서 세포치료는 오늘날 병원규모의 자기이식 모델에서 확장된 규모의 규제된 유럽<SPAN lang=EN-US>/</SPAN>글로벌 산업으로 이동할 수 있음 <SPAN lang=EN-US><SPAN style="mso-spacerun: yes">&nbsp;&nbsp;&nbsp;&nbsp;</SPAN><O:P></O:P></SPAN></SPAN></FONT></P><BR><br />
<P class=MsoNormal style="MARGIN: 0cm 0cm 0pt"><SPAN lang=EN-US style="FONT-FAMILY: 굴림; mso-bidi-font-size: 10.0pt"><O:P><FONT size=2>&nbsp;</FONT></O:P></SPAN></P><BR><br />
<P class=MsoNormal style="MARGIN: 0cm 0cm 0pt"><SPAN lang=EN-US style="FONT-FAMILY: 굴림; mso-bidi-font-size: 10.0pt"><O:P><FONT size=2>&nbsp;</FONT></O:P></SPAN></P><BR><br />
<P class=MsoNormal style="MARGIN: 0cm 0cm 0pt"><FONT size=2><SPAN lang=EN-US style="FONT-FAMILY: 굴림; mso-bidi-font-size: 10.0pt">[</SPAN><SPAN style="FONT-FAMILY: 굴림; mso-bidi-font-size: 10.0pt">목차<SPAN lang=EN-US>]<O:P></O:P></SPAN></SPAN></FONT></P><BR><br />
<P class=MsoNormal style="MARGIN: 0cm 0cm 0pt"><FONT size=2><SPAN lang=EN-US style="FONT-FAMILY: 굴림; mso-bidi-font-size: 10.0pt">- </SPAN><SPAN style="FONT-FAMILY: 굴림; mso-bidi-font-size: 10.0pt">과학과 제품<SPAN lang=EN-US>: </SPAN>재생의학과 줄기세포<SPAN lang=EN-US><O:P></O:P></SPAN></SPAN></FONT></P><BR><br />
<P class=MsoNormal style="MARGIN: 0cm 0cm 0pt"><FONT size=2><SPAN lang=EN-US style="FONT-FAMILY: 굴림; mso-bidi-font-size: 10.0pt">- </SPAN><SPAN style="FONT-FAMILY: 굴림; mso-bidi-font-size: 10.0pt">유럽의 견해<SPAN lang=EN-US>: </SPAN>재생의학과 줄기세포의 비전<SPAN lang=EN-US><O:P></O:P></SPAN></SPAN></FONT></P><BR><br />
<P class=MsoNormal style="MARGIN: 0cm 0cm 0pt"><FONT size=2><SPAN lang=EN-US style="FONT-FAMILY: 굴림; mso-bidi-font-size: 10.0pt">- </SPAN><SPAN style="FONT-FAMILY: 굴림; mso-bidi-font-size: 10.0pt">전문가 논의<SPAN lang=EN-US>: </SPAN>유럽은 재생의학의 선두를 유지하기 위해 무엇을 해야 하는가<SPAN lang=EN-US><O:P></O:P></SPAN></SPAN></FONT></P><BR><SPAN lang=EN-US style="FONT-SIZE: 10pt; FONT-FAMILY: 굴림; mso-bidi-font-family: 'Times New Roman'; mso-font-kerning: 1.0pt; mso-ansi-language: EN-US; mso-fareast-language: KO; mso-bidi-language: AR-SA">- </SPAN><SPAN style="FONT-SIZE: 10pt; FONT-FAMILY: 굴림; mso-bidi-font-family: 'Times New Roman'; mso-font-kerning: 1.0pt; mso-ansi-language: EN-US; mso-fareast-language: KO; mso-bidi-language: AR-SA">미국의 견해<SPAN lang=EN-US>: </SPAN>줄기세포 치료의 첫 승인과 정치적 촉진&nbsp;&nbsp; </SPAN><BR><BR></p>
]]></content:encoded>
			<wfw:commentRss>http://www.chsc.or.kr/?post_type=reference&#038;p=4074/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>[구제역] Community measures for the control of foot-and-mouth disease</title>
		<link>http://www.chsc.or.kr/?post_type=reference&#038;p=2509</link>
		<comments>http://www.chsc.or.kr/?post_type=reference&#038;p=2509#comments</comments>
		<pubDate>Tue, 04 Jan 2011 13:11:10 +0000</pubDate>
		<dc:creator>건강과대안</dc:creator>
				<category><![CDATA[식품 · 의약품]]></category>
		<category><![CDATA[commercial interests]]></category>
		<category><![CDATA[ethical principles]]></category>
		<category><![CDATA[EU]]></category>
		<category><![CDATA[FMD]]></category>
		<category><![CDATA[Preventive measures]]></category>
		<category><![CDATA[구제역]]></category>

		<guid isPermaLink="false">http://www.chsc.or.kr/?post_type=reference&#038;p=2509</guid>
		<description><![CDATA[COUNCIL DIRECTIVE 2003/85/ECof 29 September 2003on Community measures for the control of foot-and-mouth disease repealing Directive 85/511/EEC and Decisions 89/531/EEC and 91/665/EEC and amending Directive 92/46/EEC]]></description>
				<content:encoded><![CDATA[<p>COUNCIL DIRECTIVE 2003/85/EC<BR>of 29 September 2003<BR>on Community measures for the control of foot-and-mouth disease repealing Directive 85/511/<BR>EEC and Decisions 89/531/EEC and 91/665/EEC and amending Directive 92/46/EEC<BR></p>
]]></content:encoded>
			<wfw:commentRss>http://www.chsc.or.kr/?post_type=reference&#038;p=2509/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>[광우병] EU, 광우병 발생 시 농장전체 살처분 정책 폐기 제안</title>
		<link>http://www.chsc.or.kr/?post_type=reference&#038;p=2181</link>
		<comments>http://www.chsc.or.kr/?post_type=reference&#038;p=2181#comments</comments>
		<pubDate>Mon, 19 Jul 2010 16:44:14 +0000</pubDate>
		<dc:creator>건강과대안</dc:creator>
				<category><![CDATA[광우병]]></category>
		<category><![CDATA[식품 · 의약품]]></category>
		<category><![CDATA[EU]]></category>
		<category><![CDATA[UK]]></category>
		<category><![CDATA[교차오염]]></category>
		<category><![CDATA[사료정책]]></category>
		<category><![CDATA[살처분 정책]]></category>
		<category><![CDATA[영국]]></category>

		<guid isPermaLink="false">http://www.chsc.or.kr/?post_type=reference&#038;p=2181</guid>
		<description><![CDATA[광우병이 유럽에서 거의 근절됨에 따라 감염된 소가 발생할 경우 농장에서 사육하는 전체 소를살처분하는 정책을 폐기할 것을 제안했다는 소식입니다.Mad cow nearly eradicated in Europe: EU출처 : AFP통신 Fri&#160;Jul&#160;16, 12:01&#160;pm&#160;ET [...]]]></description>
				<content:encoded><![CDATA[<p>광우병이 유럽에서 거의 근절됨에 따라 감염된 소가 발생할 경우 농장에서 사육하는 전체 소를<BR>살처분하는 정책을 폐기할 것을 제안했다는 소식입니다.<BR><BR>Mad cow nearly eradicated in Europe: EU<BR><BR>출처 : AFP통신 Fri&nbsp;Jul&nbsp;16, 12:01&nbsp;pm&nbsp;ET</ABBR><!-- end .byline --><br />
<DIV class=yn-story-content><br />
<P>BRUSSELS (AFP) – <A class=konaYahooLink id=KonaLink0 style="BORDER-BOTTOM: #366388 2px dotted; POSITION: relative" href="http://news.yahoo.com/s/afp/20100716/bs_afp/eumadcowfoodsafetyfarm_20100716160110#" target=undefined><FONT style="FONT-WEIGHT: 400; COLOR: #366388! important; FONT-FAMILY: arial,helvetica,clean,sans-serif; POSITION: static" color=#366388><SPAN class=kLink style="FONT-WEIGHT: 400; BORDER-BOTTOM-WIDTH: 0px; COLOR: #366388! important; FONT-FAMILY: arial,helvetica,clean,sans-serif; POSITION: static">Mad </SPAN><SPAN class=kLink style="FONT-WEIGHT: 400; BORDER-BOTTOM-WIDTH: 0px; COLOR: #366388! important; FONT-FAMILY: arial,helvetica,clean,sans-serif; POSITION: static">cow </SPAN><SPAN class=kLink style="FONT-WEIGHT: 400; BORDER-BOTTOM-WIDTH: 0px; COLOR: #366388! important; FONT-FAMILY: arial,helvetica,clean,sans-serif; POSITION: static">disease</SPAN></FONT></A> is on the verge of being eradicated in Europe, the EU&#8217;s executive arm said on Friday as it proposed an end to the systematic killing of entire herds when a sick cow is discovered.</P><br />
<P>&#8220;The European Union has made great progress in its battle against BSE and we are finally on the brink of eradicating the disease within the Union,&#8221; said European Health and Consumer Policy Commissioner John Dalli.</P><br />
<P>The European Commission said the &#8220;systematic cohort culling of cattle could be stopped&#8221; because of the dramatic drop in cases of <A class=konaYahooLink id=KonaLink1 style="BORDER-BOTTOM: #366388 2px dotted; POSITION: relative; BACKGROUND-COLOR: transparent" href="http://news.yahoo.com/s/afp/20100716/bs_afp/eumadcowfoodsafetyfarm_20100716160110#" target=undefined><FONT style="FONT-WEIGHT: 400; COLOR: #366388! important; FONT-FAMILY: arial,helvetica,clean,sans-serif; POSITION: static" color=#366388><SPAN class=kLink style="FONT-WEIGHT: 400; BORDER-BOTTOM-WIDTH: 0px; COLOR: #366388! important; FONT-FAMILY: arial,helvetica,clean,sans-serif; POSITION: static">bovine </SPAN><SPAN class=kLink style="FONT-WEIGHT: 400; BORDER-BOTTOM-WIDTH: 0px; COLOR: #366388! important; FONT-FAMILY: arial,helvetica,clean,sans-serif; POSITION: static">spongiform </SPAN><SPAN class=kLink style="FONT-WEIGHT: 400; BORDER-BOTTOM-WIDTH: 0px; COLOR: #366388! important; FONT-FAMILY: arial,helvetica,clean,sans-serif; POSITION: static">encephalopathy</SPAN></FONT></A> (BSE).</P><br />
<P>Animals from herds in which a cow suffered from the disease could be sold for consumption as long as they test negative before entering the food chain, it said.</P><br />
<P>The commission also proposed to relax a ban on animal protein used in pig and poultry feed that was imposed in 2001. This would allow pig meal to be fed to poultry and poultry meal to pigs.</P><br />
<P>But it would maintain a prohibition on &#8220;intra species recycling&#8221;: the feeding of pig meal to pigs or poultry meal to poultry.</P><br />
<P>Mad cow disease was first diagnosed in Britain in 1986 before spreading to the rest of Europe.</P><br />
<P>The EU slapped a total ban on exports of British live cattle in March 1996 at the height of the mad cow crisis, after London reported a link with a new form of Creutzfeldt-Jakob disease (vCJD) in humans, connected with eating BSE-tainted beef.</P><br />
<P>The EU lifted the ban on British beef in 2006.</P><br />
<P></P></DIV></p>
]]></content:encoded>
			<wfw:commentRss>http://www.chsc.or.kr/?post_type=reference&#038;p=2181/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>[방사선조사] 방사선 조사와 수입식품(일본 자료)</title>
		<link>http://www.chsc.or.kr/?post_type=reference&#038;p=1868</link>
		<comments>http://www.chsc.or.kr/?post_type=reference&#038;p=1868#comments</comments>
		<pubDate>Tue, 16 Mar 2010 14:19:42 +0000</pubDate>
		<dc:creator>건강과대안</dc:creator>
				<category><![CDATA[식품 · 의약품]]></category>
		<category><![CDATA[EU]]></category>
		<category><![CDATA[放射線照射]]></category>
		<category><![CDATA[輸入食品]]></category>
		<category><![CDATA[미국]]></category>
		<category><![CDATA[방사선조사]]></category>
		<category><![CDATA[수입식품]]></category>
		<category><![CDATA[식품산업]]></category>
		<category><![CDATA[식품안전]]></category>
		<category><![CDATA[원자력 산업]]></category>
		<category><![CDATA[일본]]></category>

		<guid isPermaLink="false">http://www.chsc.or.kr/?post_type=reference&#038;p=1868</guid>
		<description><![CDATA[&#160; 방사선 조사와 수입식품(放射線照射と輸入食品) 저자 사토미 히로시(里見 宏): 1947년생, 국립공중위생원 연구과정 수료, 현재 건강정보연구센타 대표 아유카와 유리카(鮎川ゆりか): 1947년생, 조지대학교 외국어 학부 영어학과 졸업. 현재 원자력자료 정보실에 근무 쿠보타 [...]]]></description>
				<content:encoded><![CDATA[<p>&nbsp;<A name="[문서의 처음]"></A><br />
<P style="FONT-SIZE: 15pt; MARGIN: 0px; COLOR: #000000; TEXT-INDENT: 0px; LINE-HEIGHT: 160%; FONT-FAMILY: '바탕'; TEXT-ALIGN: center"><SPAN style="FONT-WEIGHT: bold; FONT-SIZE: 15pt; COLOR: #000000; LINE-HEIGHT: 32px; FONT-FAMILY: '바탕'; LETTER-SPACING: 0px; TEXT-ALIGN: center">방사선 조사와 수입식품(放射線照射と輸入食品)</SPAN> </P><br />
<P style="FONT-SIZE: 10pt; MARGIN: 0px; COLOR: #000000; TEXT-INDENT: 0px; LINE-HEIGHT: 160%; FONT-FAMILY: '바탕'; TEXT-ALIGN: justify"><SPAN style="FONT-SIZE: 10pt; COLOR: #000000; LINE-HEIGHT: 21px; FONT-FAMILY: '바탕'; LETTER-SPACING: 0px; TEXT-ALIGN: justify"><BR></SPAN></P><br />
<P style="FONT-SIZE: 10pt; MARGIN: 0px; COLOR: #000000; TEXT-INDENT: 0px; LINE-HEIGHT: 160%; FONT-FAMILY: '바탕'; TEXT-ALIGN: justify"><SPAN style="FONT-SIZE: 10pt; COLOR: #000000; LINE-HEIGHT: 21px; FONT-FAMILY: '바탕'; LETTER-SPACING: 0px; TEXT-ALIGN: justify">저자</SPAN> </P><br />
<P style="FONT-SIZE: 10pt; MARGIN: 0px; COLOR: #000000; TEXT-INDENT: 0px; LINE-HEIGHT: 160%; FONT-FAMILY: '바탕'; TEXT-ALIGN: justify"><SPAN style="FONT-SIZE: 10pt; COLOR: #000000; LINE-HEIGHT: 21px; FONT-FAMILY: '바탕'; LETTER-SPACING: 0px; TEXT-ALIGN: justify">사토미 히로시(里見 宏): 1947년생, 국립공중위생원 연구과정 수료, 현재 건강정보연구센타 대표</SPAN> </P><br />
<P style="FONT-SIZE: 10pt; MARGIN: 0px; COLOR: #000000; TEXT-INDENT: 0px; LINE-HEIGHT: 160%; FONT-FAMILY: '바탕'; TEXT-ALIGN: justify"><SPAN style="FONT-SIZE: 10pt; COLOR: #000000; LINE-HEIGHT: 21px; FONT-FAMILY: '바탕'; LETTER-SPACING: 0px; TEXT-ALIGN: justify">아유카와 유리카(鮎川ゆりか): 1947년생, 조지대학교 외국어 학부 영어학과 졸업. 현재 원자력자료 정보실에 근무</SPAN> </P><br />
<P style="FONT-SIZE: 10pt; MARGIN: 0px; COLOR: #000000; TEXT-INDENT: 0px; LINE-HEIGHT: 160%; FONT-FAMILY: '바탕'; TEXT-ALIGN: justify"><SPAN style="FONT-SIZE: 10pt; COLOR: #000000; LINE-HEIGHT: 21px; FONT-FAMILY: '바탕'; LETTER-SPACING: 0px; TEXT-ALIGN: justify">쿠보타 히로코(久保田裕子): 1949년생. 오챠노미즈 여자대학 가정학부 가정경영학과 졸업. 소비자 문제, 소비자 운 동등을 조사 연구</SPAN> </P><br />
<P style="FONT-SIZE: 10pt; MARGIN: 0px; COLOR: #000000; TEXT-INDENT: 0px; LINE-HEIGHT: 160%; FONT-FAMILY: '바탕'; TEXT-ALIGN: justify"><SPAN style="FONT-SIZE: 10pt; COLOR: #000000; LINE-HEIGHT: 21px; FONT-FAMILY: '바탕'; LETTER-SPACING: 0px; TEXT-ALIGN: justify">노다 카츠미(野田克己): 1952년 생. 와세다 대학 제1문학부 서양사 전공 졸업. 일본소비자연맹 사무국장 역임. 현재 세이신 여자 전문학교 보육과 교수.</SPAN> </P><br />
<P style="FONT-SIZE: 10pt; MARGIN: 0px; COLOR: #000000; TEXT-INDENT: 0px; LINE-HEIGHT: 160%; FONT-FAMILY: '바탕'; TEXT-ALIGN: justify"><SPAN style="FONT-SIZE: 10pt; COLOR: #000000; LINE-HEIGHT: 21px; FONT-FAMILY: '바탕'; LETTER-SPACING: 0px; TEXT-ALIGN: justify">하마타니 키미코(浜谷貴美子): 1943년생. 코베 시립 외국어 대학 영문과 졸업. 현재 식품 안전성에 대한 출판물 번역 활동</SPAN> </P><br />
<P style="FONT-SIZE: 10pt; MARGIN: 0px; COLOR: #000000; TEXT-INDENT: 0px; LINE-HEIGHT: 160%; FONT-FAMILY: '바탕'; TEXT-ALIGN: justify"><SPAN style="FONT-SIZE: 10pt; COLOR: #000000; LINE-HEIGHT: 21px; FONT-FAMILY: '바탕'; LETTER-SPACING: 0px; TEXT-ALIGN: justify"><BR></SPAN></P><br />
<P style="FONT-SIZE: 10pt; MARGIN: 0px; COLOR: #000000; TEXT-INDENT: 0px; LINE-HEIGHT: 160%; FONT-FAMILY: '바탕'; TEXT-ALIGN: justify"><SPAN style="FONT-SIZE: 10pt; COLOR: #000000; LINE-HEIGHT: 21px; FONT-FAMILY: '바탕'; LETTER-SPACING: 0px; TEXT-ALIGN: justify">연락처</SPAN> </P><br />
<P style="FONT-SIZE: 10pt; MARGIN: 0px; COLOR: #000000; TEXT-INDENT: 0px; LINE-HEIGHT: 160%; FONT-FAMILY: '바탕'; TEXT-ALIGN: justify"><SPAN style="FONT-SIZE: 10pt; COLOR: #000000; LINE-HEIGHT: 21px; FONT-FAMILY: '바탕'; LETTER-SPACING: 0px; TEXT-ALIGN: justify">食品照査ネットワーク（Food Irradiation Network Japan, FINJ) </SPAN></P><br />
<P style="FONT-SIZE: 10pt; MARGIN: 0px; COLOR: #000000; TEXT-INDENT: 0px; LINE-HEIGHT: 160%; FONT-FAMILY: '바탕'; TEXT-ALIGN: justify"><SPAN style="FONT-SIZE: 10pt; COLOR: #000000; LINE-HEIGHT: 21px; FONT-FAMILY: '바탕'; LETTER-SPACING: 0px; TEXT-ALIGN: justify">東京都中野区東中野 3-15-4-310</SPAN> </P><br />
<P style="FONT-SIZE: 10pt; MARGIN: 0px; COLOR: #000000; TEXT-INDENT: 0px; LINE-HEIGHT: 160%; FONT-FAMILY: '바탕'; TEXT-ALIGN: justify"><SPAN style="FONT-SIZE: 10pt; COLOR: #000000; LINE-HEIGHT: 21px; FONT-FAMILY: '바탕'; LETTER-SPACING: 0px; TEXT-ALIGN: justify">Tel 0-5386-1009, Fax 03-364-2937</SPAN> </P><br />
<P style="FONT-SIZE: 10pt; MARGIN: 0px; COLOR: #000000; TEXT-INDENT: 0px; LINE-HEIGHT: 160%; FONT-FAMILY: '바탕'; TEXT-ALIGN: justify"><SPAN style="FONT-SIZE: 10pt; COLOR: #000000; LINE-HEIGHT: 21px; FONT-FAMILY: '바탕'; LETTER-SPACING: 0px; TEXT-ALIGN: justify"><BR></SPAN></P><br />
<P style="FONT-SIZE: 10pt; MARGIN: 0px; COLOR: #000000; TEXT-INDENT: 0px; LINE-HEIGHT: 160%; FONT-FAMILY: '바탕'; TEXT-ALIGN: justify"><SPAN style="FONT-SIZE: 10pt; COLOR: #000000; LINE-HEIGHT: 21px; FONT-FAMILY: '바탕'; LETTER-SPACING: 0px; TEXT-ALIGN: justify">1990년 9월 15일 발행</SPAN> </P><br />
<P style="FONT-SIZE: 10pt; MARGIN: 0px; COLOR: #000000; TEXT-INDENT: 0px; LINE-HEIGHT: 160%; FONT-FAMILY: '바탕'; TEXT-ALIGN: justify"><SPAN style="FONT-SIZE: 10pt; COLOR: #000000; LINE-HEIGHT: 21px; FONT-FAMILY: '바탕'; LETTER-SPACING: 0px; TEXT-ALIGN: justify"><BR></SPAN></P><br />
<P style="FONT-SIZE: 10pt; MARGIN: 0px; COLOR: #000000; TEXT-INDENT: 0px; LINE-HEIGHT: 160%; FONT-FAMILY: '바탕'; TEXT-ALIGN: justify"><SPAN style="FONT-SIZE: 10pt; COLOR: #000000; LINE-HEIGHT: 21px; FONT-FAMILY: '바탕'; LETTER-SPACING: 0px; TEXT-ALIGN: justify">발행소</SPAN> </P><br />
<P style="FONT-SIZE: 10pt; MARGIN: 0px; COLOR: #000000; TEXT-INDENT: 0px; LINE-HEIGHT: 160%; FONT-FAMILY: '바탕'; TEXT-ALIGN: justify"><SPAN style="FONT-SIZE: 10pt; COLOR: #000000; LINE-HEIGHT: 21px; FONT-FAMILY: '바탕'; LETTER-SPACING: 0px; TEXT-ALIGN: justify">주식회사 北斗出版</SPAN> </P><br />
<P style="FONT-SIZE: 10pt; MARGIN: 0px; COLOR: #000000; TEXT-INDENT: 0px; LINE-HEIGHT: 160%; FONT-FAMILY: '바탕'; TEXT-ALIGN: justify"><SPAN style="FONT-SIZE: 10pt; COLOR: #000000; LINE-HEIGHT: 21px; FONT-FAMILY: '바탕'; LETTER-SPACING: 0px; TEXT-ALIGN: justify">東京都千代田区神田神保町 1-8 第一野口</SPAN><SPAN style="FONT-SIZE: 10pt; COLOR: #000000; LINE-HEIGHT: 21px; FONT-FAMILY: '바탕'; LETTER-SPACING: 0px; TEXT-ALIGN: justify">ビル</SPAN><SPAN style="FONT-SIZE: 10pt; COLOR: #000000; LINE-HEIGHT: 21px; FONT-FAMILY: '바탕'; LETTER-SPACING: 0px; TEXT-ALIGN: justify"></SPAN> </P><br />
<P style="FONT-SIZE: 10pt; MARGIN: 0px; COLOR: #000000; TEXT-INDENT: 0px; LINE-HEIGHT: 160%; FONT-FAMILY: '바탕'; TEXT-ALIGN: justify"><SPAN style="FONT-SIZE: 10pt; COLOR: #000000; LINE-HEIGHT: 21px; FONT-FAMILY: '바탕'; LETTER-SPACING: 0px; TEXT-ALIGN: justify">Tel 03-291-3258,&nbsp; Fax 03-291-2074</SPAN> </P><br />
<P style="FONT-SIZE: 10pt; MARGIN: 0px; COLOR: #000000; TEXT-INDENT: 0px; LINE-HEIGHT: 160%; FONT-FAMILY: '바탕'; TEXT-ALIGN: justify"><SPAN style="FONT-SIZE: 10pt; COLOR: #000000; LINE-HEIGHT: 21px; FONT-FAMILY: '바탕'; LETTER-SPACING: 0px; TEXT-ALIGN: justify"><BR></SPAN></P><br />
<P style="FONT-SIZE: 10pt; MARGIN: 0px; COLOR: #000000; TEXT-INDENT: 0px; LINE-HEIGHT: 160%; FONT-FAMILY: '바탕'; TEXT-ALIGN: justify"><SPAN style="FONT-SIZE: 10pt; COLOR: #000000; LINE-HEIGHT: 21px; FONT-FAMILY: '바탕'; LETTER-SPACING: 0px; TEXT-ALIGN: justify">목차</SPAN> </P><br />
<P style="FONT-SIZE: 10pt; MARGIN: 0px; COLOR: #000000; TEXT-INDENT: 0px; LINE-HEIGHT: 160%; FONT-FAMILY: '바탕'; TEXT-ALIGN: justify"><SPAN style="FONT-SIZE: 10pt; COLOR: #000000; LINE-HEIGHT: 21px; FONT-FAMILY: '바탕'; LETTER-SPACING: 0px; TEXT-ALIGN: justify"><BR></SPAN></P><br />
<P style="FONT-SIZE: 10pt; MARGIN: 0px; COLOR: #000000; TEXT-INDENT: 0px; LINE-HEIGHT: 160%; FONT-FAMILY: '바탕'; TEXT-ALIGN: justify"><SPAN style="FONT-SIZE: 10pt; COLOR: #000000; LINE-HEIGHT: 21px; FONT-FAMILY: '바탕'; LETTER-SPACING: 0px; TEXT-ALIGN: justify">프롤로그&nbsp;&nbsp; i</SPAN> </P><br />
<P style="FONT-SIZE: 10pt; MARGIN: 0px; COLOR: #000000; TEXT-INDENT: 0px; LINE-HEIGHT: 160%; FONT-FAMILY: '바탕'; TEXT-ALIGN: justify"><SPAN style="FONT-SIZE: 10pt; COLOR: #000000; LINE-HEIGHT: 21px; FONT-FAMILY: '바탕'; LETTER-SPACING: 0px; TEXT-ALIGN: justify"><BR></SPAN></P><br />
<P style="FONT-SIZE: 10pt; MARGIN: 0px; COLOR: #000000; TEXT-INDENT: 0px; LINE-HEIGHT: 160%; FONT-FAMILY: '바탕'; TEXT-ALIGN: justify"><SPAN style="FONT-SIZE: 10pt; COLOR: #000000; LINE-HEIGHT: 21px; FONT-FAMILY: '바탕'; LETTER-SPACING: 0px; TEXT-ALIGN: justify">제1장&nbsp; 식품의 반대 극단에 있는 조사식품&nbsp;&nbsp; 1</SPAN> </P><br />
<P style="FONT-SIZE: 10pt; MARGIN: 0px; COLOR: #000000; TEXT-INDENT: 0px; LINE-HEIGHT: 160%; FONT-FAMILY: '바탕'; TEXT-ALIGN: justify"><SPAN style="FONT-SIZE: 10pt; COLOR: #000000; LINE-HEIGHT: 21px; FONT-FAMILY: '바탕'; LETTER-SPACING: 0px; TEXT-ALIGN: justify">1. 인간에게 있어서 먹을거리란&nbsp;&nbsp; 2 </SPAN></P><br />
<P style="FONT-SIZE: 10pt; MARGIN: 0px; COLOR: #000000; TEXT-INDENT: 0px; LINE-HEIGHT: 160%; FONT-FAMILY: '바탕'; TEXT-ALIGN: justify"><SPAN style="FONT-SIZE: 10pt; COLOR: #000000; LINE-HEIGHT: 21px; FONT-FAMILY: '바탕'; LETTER-SPACING: 0px; TEXT-ALIGN: justify">2. 식품 조사(照射)의 구조&nbsp;&nbsp; 5 </SPAN></P><br />
<P style="FONT-SIZE: 10pt; MARGIN: 0px; COLOR: #000000; TEXT-INDENT: 0px; LINE-HEIGHT: 160%; FONT-FAMILY: '바탕'; TEXT-ALIGN: justify"><SPAN style="FONT-SIZE: 10pt; COLOR: #000000; LINE-HEIGHT: 21px; FONT-FAMILY: '바탕'; LETTER-SPACING: 0px; TEXT-ALIGN: justify">3. 조사(照射) 식품은 먹을거리인가?&nbsp;&nbsp; 10 </SPAN></P><br />
<P style="FONT-SIZE: 10pt; MARGIN: 0px; COLOR: #000000; TEXT-INDENT: 0px; LINE-HEIGHT: 160%; FONT-FAMILY: '바탕'; TEXT-ALIGN: justify"><SPAN style="FONT-SIZE: 10pt; COLOR: #000000; LINE-HEIGHT: 21px; FONT-FAMILY: '바탕'; LETTER-SPACING: 0px; TEXT-ALIGN: justify">4. 식품의 질과 안전성을 낮추는 조사식품&nbsp;&nbsp; 14</SPAN> </P><br />
<P style="FONT-SIZE: 10pt; MARGIN: 0px; COLOR: #000000; TEXT-INDENT: 0px; LINE-HEIGHT: 160%; FONT-FAMILY: '바탕'; TEXT-ALIGN: justify"><SPAN style="FONT-SIZE: 10pt; COLOR: #000000; LINE-HEIGHT: 21px; FONT-FAMILY: '바탕'; LETTER-SPACING: 0px; TEXT-ALIGN: justify"><BR></SPAN></P><br />
<P style="FONT-SIZE: 10pt; MARGIN: 0px; COLOR: #000000; TEXT-INDENT: 0px; LINE-HEIGHT: 160%; FONT-FAMILY: '바탕'; TEXT-ALIGN: justify"><SPAN style="FONT-SIZE: 10pt; COLOR: #000000; LINE-HEIGHT: 21px; FONT-FAMILY: '바탕'; LETTER-SPACING: 0px; TEXT-ALIGN: justify">제2장&nbsp; ‘이점’의 검증 &#8211; 조사식품의 효능은?&nbsp;&nbsp; 19</SPAN> </P><br />
<P style="FONT-SIZE: 10pt; MARGIN: 0px; COLOR: #000000; TEXT-INDENT: 0px; LINE-HEIGHT: 160%; FONT-FAMILY: '바탕'; TEXT-ALIGN: justify"><SPAN style="FONT-SIZE: 10pt; COLOR: #000000; LINE-HEIGHT: 21px; FONT-FAMILY: '바탕'; LETTER-SPACING: 0px; TEXT-ALIGN: justify">1. 조사식품에의 의문&nbsp;&nbsp; 20</SPAN> </P><br />
<P style="FONT-SIZE: 10pt; MARGIN: 0px; COLOR: #000000; TEXT-INDENT: 0px; LINE-HEIGHT: 160%; FONT-FAMILY: '바탕'; TEXT-ALIGN: justify"><SPAN style="FONT-SIZE: 10pt; COLOR: #000000; LINE-HEIGHT: 21px; FONT-FAMILY: '바탕'; LETTER-SPACING: 0px; TEXT-ALIGN: justify">2. 일본에 있어서 조사식품 개발의 발자취&nbsp;&nbsp; 24</SPAN> </P><br />
<P style="FONT-SIZE: 10pt; MARGIN: 0px; COLOR: #000000; TEXT-INDENT: 0px; LINE-HEIGHT: 160%; FONT-FAMILY: '바탕'; TEXT-ALIGN: justify"><SPAN style="FONT-SIZE: 10pt; COLOR: #000000; LINE-HEIGHT: 21px; FONT-FAMILY: '바탕'; LETTER-SPACING: 0px; TEXT-ALIGN: justify">3. 조사식품에 이점은 있을까?&nbsp;&nbsp; 27</SPAN> </P><br />
<P style="FONT-SIZE: 10pt; MARGIN: 0px; COLOR: #000000; TEXT-INDENT: 0px; LINE-HEIGHT: 160%; FONT-FAMILY: '바탕'; TEXT-ALIGN: justify"><SPAN style="FONT-SIZE: 10pt; COLOR: #000000; LINE-HEIGHT: 21px; FONT-FAMILY: '바탕'; LETTER-SPACING: 0px; TEXT-ALIGN: justify">4. 악용의 예&nbsp;&nbsp; 41</SPAN> </P><br />
<P style="FONT-SIZE: 10pt; MARGIN: 0px; COLOR: #000000; TEXT-INDENT: 0px; LINE-HEIGHT: 160%; FONT-FAMILY: '바탕'; TEXT-ALIGN: justify"><SPAN style="FONT-SIZE: 10pt; COLOR: #000000; LINE-HEIGHT: 21px; FONT-FAMILY: '바탕'; LETTER-SPACING: 0px; TEXT-ALIGN: justify">5. 근거가 없는 “100만 라드까지는 안전하다”는 견해&nbsp;&nbsp; 42</SPAN> </P><br />
<P style="FONT-SIZE: 10pt; MARGIN: 0px; COLOR: #000000; TEXT-INDENT: 0px; LINE-HEIGHT: 160%; FONT-FAMILY: '바탕'; TEXT-ALIGN: justify"><SPAN style="FONT-SIZE: 10pt; COLOR: #000000; LINE-HEIGHT: 21px; FONT-FAMILY: '바탕'; LETTER-SPACING: 0px; TEXT-ALIGN: justify"><BR></SPAN></P><br />
<P style="FONT-SIZE: 10pt; MARGIN: 0px; COLOR: #000000; TEXT-INDENT: 0px; LINE-HEIGHT: 160%; FONT-FAMILY: '바탕'; TEXT-ALIGN: justify"><SPAN style="FONT-SIZE: 10pt; COLOR: #000000; LINE-HEIGHT: 21px; FONT-FAMILY: '바탕'; LETTER-SPACING: 0px; TEXT-ALIGN: justify">제3장&nbsp; 생명의 양식을 위협해&nbsp; 들어오는 원자력 산업&nbsp;&nbsp; 45</SPAN> </P><br />
<P style="FONT-SIZE: 10pt; MARGIN: 0px; COLOR: #000000; TEXT-INDENT: 0px; LINE-HEIGHT: 160%; FONT-FAMILY: '바탕'; TEXT-ALIGN: justify"><SPAN style="FONT-SIZE: 10pt; COLOR: #000000; LINE-HEIGHT: 21px; FONT-FAMILY: '바탕'; LETTER-SPACING: 0px; TEXT-ALIGN: justify">1. 또 하나의 핵, 식품조사&nbsp;&nbsp; 46</SPAN> </P><br />
<P style="FONT-SIZE: 10pt; MARGIN: 0px; COLOR: #000000; TEXT-INDENT: 0px; LINE-HEIGHT: 160%; FONT-FAMILY: '바탕'; TEXT-ALIGN: justify"><SPAN style="FONT-SIZE: 10pt; COLOR: #000000; LINE-HEIGHT: 21px; FONT-FAMILY: '바탕'; LETTER-SPACING: 0px; TEXT-ALIGN: justify">2. 조사식품의 판매계획 시나리오&nbsp;&nbsp; 51</SPAN> </P><br />
<P style="FONT-SIZE: 10pt; MARGIN: 0px; COLOR: #000000; TEXT-INDENT: 0px; LINE-HEIGHT: 160%; FONT-FAMILY: '바탕'; TEXT-ALIGN: justify"><SPAN style="FONT-SIZE: 10pt; COLOR: #000000; LINE-HEIGHT: 21px; FONT-FAMILY: '바탕'; LETTER-SPACING: 0px; TEXT-ALIGN: justify">3. ‘조사식품의 수용, 관리 및 무역에 관한 국제회의’&nbsp;&nbsp; 57</SPAN> </P><br />
<P style="FONT-SIZE: 10pt; MARGIN: 0px; COLOR: #000000; TEXT-INDENT: 0px; LINE-HEIGHT: 160%; FONT-FAMILY: '바탕'; TEXT-ALIGN: justify"><SPAN style="FONT-SIZE: 10pt; COLOR: #000000; LINE-HEIGHT: 21px; FONT-FAMILY: '바탕'; LETTER-SPACING: 0px; TEXT-ALIGN: justify">4. 일본은 아시아와 어떻게 관련되어 있는가&nbsp;&nbsp; 67</SPAN> </P><br />
<P style="FONT-SIZE: 10pt; MARGIN: 0px; COLOR: #000000; TEXT-INDENT: 0px; LINE-HEIGHT: 160%; FONT-FAMILY: '바탕'; TEXT-ALIGN: justify"><SPAN style="FONT-SIZE: 10pt; COLOR: #000000; LINE-HEIGHT: 21px; FONT-FAMILY: '바탕'; LETTER-SPACING: 0px; TEXT-ALIGN: justify">5. 식품조사 반대운동도 반핵운동과 함께&nbsp;&nbsp; 70</SPAN> </P><br />
<P style="FONT-SIZE: 10pt; MARGIN: 0px; COLOR: #000000; TEXT-INDENT: 0px; LINE-HEIGHT: 160%; FONT-FAMILY: '바탕'; TEXT-ALIGN: justify"><SPAN style="FONT-SIZE: 10pt; COLOR: #000000; LINE-HEIGHT: 21px; FONT-FAMILY: '바탕'; LETTER-SPACING: 0px; TEXT-ALIGN: justify"><BR></SPAN></P><br />
<P style="FONT-SIZE: 10pt; MARGIN: 0px; COLOR: #000000; TEXT-INDENT: 0px; LINE-HEIGHT: 160%; FONT-FAMILY: '바탕'; TEXT-ALIGN: justify"><SPAN style="FONT-SIZE: 10pt; COLOR: #000000; LINE-HEIGHT: 21px; FONT-FAMILY: '바탕'; LETTER-SPACING: 0px; TEXT-ALIGN: justify">제4장&nbsp; 조사식품은 안전한가 &#8211; 독성실험의 데이터 분석으로부터&nbsp;&nbsp; 75</SPAN> </P><br />
<P style="FONT-SIZE: 10pt; MARGIN: 0px; COLOR: #000000; TEXT-INDENT: 0px; LINE-HEIGHT: 160%; FONT-FAMILY: '바탕'; TEXT-ALIGN: justify"><SPAN style="FONT-SIZE: 10pt; COLOR: #000000; LINE-HEIGHT: 21px; FONT-FAMILY: '바탕'; LETTER-SPACING: 0px; TEXT-ALIGN: justify">1. 조사식품의 일반적 문제점&nbsp;&nbsp; 77</SPAN> </P><br />
<P style="FONT-SIZE: 10pt; MARGIN: 0px; COLOR: #000000; TEXT-INDENT: 0px; LINE-HEIGHT: 160%; FONT-FAMILY: '바탕'; TEXT-ALIGN: justify"><SPAN style="FONT-SIZE: 10pt; COLOR: #000000; LINE-HEIGHT: 21px; FONT-FAMILY: '바탕'; LETTER-SPACING: 0px; TEXT-ALIGN: justify">2. 미국 조사식품 인가 취소 사건에서 보는 문제점&nbsp;&nbsp; 83</SPAN> </P><br />
<P style="FONT-SIZE: 10pt; MARGIN: 0px; COLOR: #000000; TEXT-INDENT: 0px; LINE-HEIGHT: 160%; FONT-FAMILY: '바탕'; TEXT-ALIGN: justify"><SPAN style="FONT-SIZE: 10pt; COLOR: #000000; LINE-HEIGHT: 21px; FONT-FAMILY: '바탕'; LETTER-SPACING: 0px; TEXT-ALIGN: justify">3. 러시아의 실험에서 보는 문제점&nbsp;&nbsp; 85</SPAN> </P><br />
<P style="FONT-SIZE: 10pt; MARGIN: 0px; COLOR: #000000; TEXT-INDENT: 0px; LINE-HEIGHT: 160%; FONT-FAMILY: '바탕'; TEXT-ALIGN: justify"><SPAN style="FONT-SIZE: 10pt; COLOR: #000000; LINE-HEIGHT: 21px; FONT-FAMILY: '바탕'; LETTER-SPACING: 0px; TEXT-ALIGN: justify">4. 인도의 실험에서 보는 문제점&nbsp;&nbsp; 89</SPAN> </P><br />
<P style="FONT-SIZE: 10pt; MARGIN: 0px; COLOR: #000000; TEXT-INDENT: 0px; LINE-HEIGHT: 160%; FONT-FAMILY: '바탕'; TEXT-ALIGN: justify"><SPAN style="FONT-SIZE: 10pt; COLOR: #000000; LINE-HEIGHT: 21px; FONT-FAMILY: '바탕'; LETTER-SPACING: 0px; TEXT-ALIGN: justify">5. 중국에서의 인체실험에서 보는 문제점&nbsp;&nbsp; 98</SPAN> </P><br />
<P style="FONT-SIZE: 10pt; MARGIN: 0px; COLOR: #000000; TEXT-INDENT: 0px; LINE-HEIGHT: 160%; FONT-FAMILY: '바탕'; TEXT-ALIGN: justify"><SPAN style="FONT-SIZE: 10pt; COLOR: #000000; LINE-HEIGHT: 21px; FONT-FAMILY: '바탕'; LETTER-SPACING: 0px; TEXT-ALIGN: justify">6. 일본에서 행해진 독성실험 &#8211; 조사식품 연구성과 보고서로부터&nbsp;&nbsp; 102</SPAN> </P><br />
<P style="FONT-SIZE: 10pt; MARGIN: 0px; COLOR: #000000; TEXT-INDENT: 0px; LINE-HEIGHT: 160%; FONT-FAMILY: '바탕'; TEXT-ALIGN: justify"><SPAN style="FONT-SIZE: 10pt; COLOR: #000000; LINE-HEIGHT: 21px; FONT-FAMILY: '바탕'; LETTER-SPACING: 0px; TEXT-ALIGN: justify">7. 조사식품은 위험한 먹을거리&nbsp;&nbsp; 140</SPAN> </P><br />
<P style="FONT-SIZE: 10pt; MARGIN: 0px; COLOR: #000000; TEXT-INDENT: 0px; LINE-HEIGHT: 160%; FONT-FAMILY: '바탕'; TEXT-ALIGN: justify"><SPAN style="FONT-SIZE: 10pt; COLOR: #000000; LINE-HEIGHT: 21px; FONT-FAMILY: '바탕'; LETTER-SPACING: 0px; TEXT-ALIGN: justify"><BR></SPAN></P><br />
<P style="FONT-SIZE: 10pt; MARGIN: 0px; COLOR: #000000; TEXT-INDENT: 0px; LINE-HEIGHT: 160%; FONT-FAMILY: '바탕'; TEXT-ALIGN: justify"><SPAN style="FONT-SIZE: 10pt; COLOR: #000000; LINE-HEIGHT: 21px; FONT-FAMILY: '바탕'; LETTER-SPACING: 0px; TEXT-ALIGN: justify">제5장&nbsp; 조사를 둘러싼 지구적 투쟁&nbsp;&nbsp; 145</SPAN> </P><br />
<P style="FONT-SIZE: 10pt; MARGIN: 0px; COLOR: #000000; TEXT-INDENT: 0px; LINE-HEIGHT: 160%; FONT-FAMILY: '바탕'; TEXT-ALIGN: justify"><SPAN style="FONT-SIZE: 10pt; COLOR: #000000; LINE-HEIGHT: 21px; FONT-FAMILY: '바탕'; LETTER-SPACING: 0px; TEXT-ALIGN: justify">1. 국제유통을 노리는 조사식품&nbsp;&nbsp; 146</SPAN> </P><br />
<P style="FONT-SIZE: 10pt; MARGIN: 0px; COLOR: #000000; TEXT-INDENT: 0px; LINE-HEIGHT: 160%; FONT-FAMILY: '바탕'; TEXT-ALIGN: justify"><SPAN style="FONT-SIZE: 10pt; COLOR: #000000; LINE-HEIGHT: 21px; FONT-FAMILY: '바탕'; LETTER-SPACING: 0px; TEXT-ALIGN: justify">2. 추진에 대해 끈질기게 반대하는 미국&nbsp;&nbsp; 148</SPAN> </P><br />
<P style="FONT-SIZE: 10pt; MARGIN: 0px; COLOR: #000000; TEXT-INDENT: 0px; LINE-HEIGHT: 160%; FONT-FAMILY: '바탕'; TEXT-ALIGN: justify"><SPAN style="FONT-SIZE: 10pt; COLOR: #000000; LINE-HEIGHT: 21px; FONT-FAMILY: '바탕'; LETTER-SPACING: 0px; TEXT-ALIGN: justify">3. 아시아에 퍼져가는 식품조사&nbsp;&nbsp; 156</SPAN> </P><br />
<P style="FONT-SIZE: 10pt; MARGIN: 0px; COLOR: #000000; TEXT-INDENT: 0px; LINE-HEIGHT: 160%; FONT-FAMILY: '바탕'; TEXT-ALIGN: justify"><SPAN style="FONT-SIZE: 10pt; COLOR: #000000; LINE-HEIGHT: 21px; FONT-FAMILY: '바탕'; LETTER-SPACING: 0px; TEXT-ALIGN: justify">4. 걱정되는 EU, 영국 추진의 움직임&nbsp;&nbsp; 163</SPAN> </P><br />
<P style="FONT-SIZE: 10pt; MARGIN: 0px; COLOR: #000000; TEXT-INDENT: 0px; LINE-HEIGHT: 160%; FONT-FAMILY: '바탕'; TEXT-ALIGN: justify"><SPAN style="FONT-SIZE: 10pt; COLOR: #000000; LINE-HEIGHT: 21px; FONT-FAMILY: '바탕'; LETTER-SPACING: 0px; TEXT-ALIGN: justify">5. 식품조사에 반대하는 나라들&nbsp;&nbsp; 166</SPAN> </P><br />
<P style="FONT-SIZE: 10pt; MARGIN: 0px; COLOR: #000000; TEXT-INDENT: 0px; LINE-HEIGHT: 160%; FONT-FAMILY: '바탕'; TEXT-ALIGN: justify"><SPAN style="FONT-SIZE: 10pt; COLOR: #000000; LINE-HEIGHT: 21px; FONT-FAMILY: '바탕'; LETTER-SPACING: 0px; TEXT-ALIGN: justify">6. 식품조사의 ‘국제화’에 소비자는 반대한다&nbsp;&nbsp; 168</SPAN> </P><br />
<P style="FONT-SIZE: 10pt; MARGIN: 0px; COLOR: #000000; TEXT-INDENT: 0px; LINE-HEIGHT: 160%; FONT-FAMILY: '바탕'; TEXT-ALIGN: justify"><SPAN style="FONT-SIZE: 10pt; COLOR: #000000; LINE-HEIGHT: 21px; FONT-FAMILY: '바탕'; LETTER-SPACING: 0px; TEXT-ALIGN: justify"><BR></SPAN></P><br />
<P style="FONT-SIZE: 10pt; MARGIN: 0px; COLOR: #000000; TEXT-INDENT: 0px; LINE-HEIGHT: 160%; FONT-FAMILY: '바탕'; TEXT-ALIGN: justify"><SPAN style="FONT-SIZE: 10pt; COLOR: #000000; LINE-HEIGHT: 21px; FONT-FAMILY: '바탕'; LETTER-SPACING: 0px; TEXT-ALIGN: justify">제6장&nbsp; 조사식품 필요 없다 &#8211; 일본 소비자의 의무를 묻는다&nbsp;&nbsp; 171</SPAN> </P><br />
<P style="FONT-SIZE: 10pt; MARGIN: 0px; COLOR: #000000; TEXT-INDENT: 0px; LINE-HEIGHT: 160%; FONT-FAMILY: '바탕'; TEXT-ALIGN: justify"><SPAN style="FONT-SIZE: 10pt; COLOR: #000000; LINE-HEIGHT: 21px; FONT-FAMILY: '바탕'; LETTER-SPACING: 0px; TEXT-ALIGN: justify">1. 조사 감자 추방운동 시작하다&nbsp;&nbsp; 172</SPAN> </P><br />
<P style="FONT-SIZE: 10pt; MARGIN: 0px; COLOR: #000000; TEXT-INDENT: 0px; LINE-HEIGHT: 160%; FONT-FAMILY: '바탕'; TEXT-ALIGN: justify"><SPAN style="FONT-SIZE: 10pt; COLOR: #000000; LINE-HEIGHT: 21px; FONT-FAMILY: '바탕'; LETTER-SPACING: 0px; TEXT-ALIGN: justify">2. 안전성 논의 스타트&nbsp;&nbsp; 175</SPAN> </P><br />
<P style="FONT-SIZE: 10pt; MARGIN: 0px; COLOR: #000000; TEXT-INDENT: 0px; LINE-HEIGHT: 160%; FONT-FAMILY: '바탕'; TEXT-ALIGN: justify"><SPAN style="FONT-SIZE: 10pt; COLOR: #000000; LINE-HEIGHT: 21px; FONT-FAMILY: '바탕'; LETTER-SPACING: 0px; TEXT-ALIGN: justify">3. 조사 베이비푸드 사건 발각&nbsp;&nbsp; 177</SPAN> </P><br />
<P style="FONT-SIZE: 10pt; MARGIN: 0px; COLOR: #000000; TEXT-INDENT: 0px; LINE-HEIGHT: 160%; FONT-FAMILY: '바탕'; TEXT-ALIGN: justify"><SPAN style="FONT-SIZE: 10pt; COLOR: #000000; LINE-HEIGHT: 21px; FONT-FAMILY: '바탕'; LETTER-SPACING: 0px; TEXT-ALIGN: justify">4. 조사 베이비푸드의 교훈&nbsp;&nbsp;&nbsp; 179</SPAN> </P><br />
<P style="FONT-SIZE: 10pt; MARGIN: 0px; COLOR: #000000; TEXT-INDENT: 0px; LINE-HEIGHT: 160%; FONT-FAMILY: '바탕'; TEXT-ALIGN: justify"><SPAN style="FONT-SIZE: 10pt; COLOR: #000000; LINE-HEIGHT: 21px; FONT-FAMILY: '바탕'; LETTER-SPACING: 0px; TEXT-ALIGN: justify">5. 원자력 산업의 세계전략으로서의 식품조사&nbsp;&nbsp;&nbsp; 184</SPAN> </P><br />
<P style="FONT-SIZE: 10pt; MARGIN: 0px; COLOR: #000000; TEXT-INDENT: 0px; LINE-HEIGHT: 160%; FONT-FAMILY: '바탕'; TEXT-ALIGN: justify"><SPAN style="FONT-SIZE: 10pt; COLOR: #000000; LINE-HEIGHT: 21px; FONT-FAMILY: '바탕'; LETTER-SPACING: 0px; TEXT-ALIGN: justify">6. 국제연대로 나아가는 조사식품반대운동&nbsp;&nbsp; 186</SPAN> </P><br />
<P style="FONT-SIZE: 10pt; MARGIN: 0px; COLOR: #000000; TEXT-INDENT: 0px; LINE-HEIGHT: 160%; FONT-FAMILY: '바탕'; TEXT-ALIGN: justify"><SPAN style="FONT-SIZE: 10pt; COLOR: #000000; LINE-HEIGHT: 21px; FONT-FAMILY: '바탕'; LETTER-SPACING: 0px; TEXT-ALIGN: justify">7. ‘식품조사 네트워크’ 시동&nbsp;&nbsp; 193</SPAN> </P><br />
<P style="FONT-SIZE: 10pt; MARGIN: 0px; COLOR: #000000; TEXT-INDENT: 0px; LINE-HEIGHT: 160%; FONT-FAMILY: '바탕'; TEXT-ALIGN: justify"><SPAN style="FONT-SIZE: 10pt; COLOR: #000000; LINE-HEIGHT: 21px; FONT-FAMILY: '바탕'; LETTER-SPACING: 0px; TEXT-ALIGN: justify"><BR></SPAN></P><br />
<P style="FONT-SIZE: 10pt; MARGIN: 0px; COLOR: #000000; TEXT-INDENT: 0px; LINE-HEIGHT: 160%; FONT-FAMILY: '바탕'; TEXT-ALIGN: justify"><SPAN style="FONT-SIZE: 10pt; COLOR: #000000; LINE-HEIGHT: 21px; FONT-FAMILY: '바탕'; LETTER-SPACING: 0px; TEXT-ALIGN: justify">자료: 관련연표&nbsp;&nbsp; 202</SPAN> </P><br />
<P style="FONT-SIZE: 10pt; MARGIN: 0px; COLOR: #000000; TEXT-INDENT: 0px; LINE-HEIGHT: 160%; FONT-FAMILY: '바탕'; TEXT-ALIGN: justify"><SPAN style="FONT-SIZE: 10pt; COLOR: #000000; LINE-HEIGHT: 21px; FONT-FAMILY: '바탕'; LETTER-SPACING: 0px; TEXT-ALIGN: justify">후기&nbsp;&nbsp; 206</SPAN> </P><br />
<P style="FONT-SIZE: 10pt; MARGIN: 0px; COLOR: #000000; TEXT-INDENT: 0px; LINE-HEIGHT: 160%; FONT-FAMILY: '바탕'; TEXT-ALIGN: justify"><SPAN style="FONT-SIZE: 10pt; COLOR: #000000; LINE-HEIGHT: 21px; FONT-FAMILY: '바탕'; LETTER-SPACING: 0px; TEXT-ALIGN: justify"><BR></SPAN></P><br />
<P style="FONT-SIZE: 10pt; MARGIN: 0px; COLOR: #000000; TEXT-INDENT: 0px; LINE-HEIGHT: 160%; FONT-FAMILY: '바탕'; TEXT-ALIGN: justify"><SPAN style="FONT-SIZE: 10pt; COLOR: #000000; LINE-HEIGHT: 21px; FONT-FAMILY: '바탕'; LETTER-SPACING: 0px; TEXT-ALIGN: justify">칼럼</SPAN> </P><br />
<P style="FONT-SIZE: 10pt; MARGIN: 0px; COLOR: #000000; TEXT-INDENT: 0px; LINE-HEIGHT: 160%; FONT-FAMILY: '바탕'; TEXT-ALIGN: justify"><SPAN style="FONT-SIZE: 10pt; COLOR: #000000; LINE-HEIGHT: 21px; FONT-FAMILY: '바탕'; LETTER-SPACING: 0px; TEXT-ALIGN: justify">단위변경의 속임수&nbsp;&nbsp; 8</SPAN> </P><br />
<P style="FONT-SIZE: 10pt; MARGIN: 0px; COLOR: #000000; TEXT-INDENT: 0px; LINE-HEIGHT: 160%; FONT-FAMILY: '바탕'; TEXT-ALIGN: justify"><SPAN style="FONT-SIZE: 10pt; COLOR: #000000; LINE-HEIGHT: 21px; FONT-FAMILY: '바탕'; LETTER-SPACING: 0px; TEXT-ALIGN: justify">조사 감자의 개발연구비용(일본)&nbsp;&nbsp; 26</SPAN> </P><br />
<P style="FONT-SIZE: 10pt; MARGIN: 0px; COLOR: #000000; TEXT-INDENT: 0px; LINE-HEIGHT: 160%; FONT-FAMILY: '바탕'; TEXT-ALIGN: justify"><SPAN style="FONT-SIZE: 10pt; COLOR: #000000; LINE-HEIGHT: 21px; FONT-FAMILY: '바탕'; LETTER-SPACING: 0px; TEXT-ALIGN: justify">식품위생법에서의 조사식품의 규정&nbsp;&nbsp; 44</SPAN> </P><br />
<P style="FONT-SIZE: 10pt; MARGIN: 0px; COLOR: #000000; TEXT-INDENT: 0px; LINE-HEIGHT: 160%; FONT-FAMILY: '바탕'; TEXT-ALIGN: justify"><SPAN style="FONT-SIZE: 10pt; COLOR: #000000; LINE-HEIGHT: 21px; FONT-FAMILY: '바탕'; LETTER-SPACING: 0px; TEXT-ALIGN: justify">동물실험의 종류&nbsp;&nbsp; 104</SPAN> </P><br />
<P style="FONT-SIZE: 10pt; MARGIN: 0px; COLOR: #000000; TEXT-INDENT: 0px; LINE-HEIGHT: 160%; FONT-FAMILY: '바탕'; TEXT-ALIGN: justify"><SPAN style="FONT-SIZE: 10pt; COLOR: #000000; LINE-HEIGHT: 21px; FONT-FAMILY: '바탕'; LETTER-SPACING: 0px; TEXT-ALIGN: justify">추진측이 말하는 ‘건전성’이란&nbsp;&nbsp; 141</SPAN> </P><br />
<P style="FONT-SIZE: 10pt; MARGIN: 0px; COLOR: #000000; TEXT-INDENT: 0px; LINE-HEIGHT: 160%; FONT-FAMILY: '바탕'; TEXT-ALIGN: justify"><SPAN style="FONT-SIZE: 10pt; COLOR: #000000; LINE-HEIGHT: 21px; FONT-FAMILY: '바탕'; LETTER-SPACING: 0px; TEXT-ALIGN: justify"><BR></SPAN></P><br />
<P style="FONT-SIZE: 10pt; MARGIN: 0px; COLOR: #000000; TEXT-INDENT: 0px; LINE-HEIGHT: 160%; FONT-FAMILY: '바탕'; TEXT-ALIGN: justify"><SPAN style="FONT-SIZE: 10pt; COLOR: #000000; LINE-HEIGHT: 21px; FONT-FAMILY: '바탕'; LETTER-SPACING: 0px; TEXT-ALIGN: justify">그림 1. 방사선의 종류&nbsp;&nbsp; 5</SPAN> </P><br />
<P style="FONT-SIZE: 10pt; MARGIN: 0px; COLOR: #000000; TEXT-INDENT: 13px; LINE-HEIGHT: 160%; FONT-FAMILY: '바탕'; TEXT-ALIGN: justify"><SPAN style="FONT-SIZE: 10pt; COLOR: #000000; LINE-HEIGHT: 21px; FONT-FAMILY: '바탕'; LETTER-SPACING: 0px; TEXT-ALIGN: justify">그림 2 식품조사 연구개발 기본계획과 실시계획&nbsp;&nbsp; 22</SPAN><SPAN style="FONT-SIZE: 10pt; COLOR: #000000; LINE-HEIGHT: 21px; FONT-FAMILY: '바탕'; LETTER-SPACING: 0px; TEXT-ALIGN: justify"></SPAN> </P><br />
<P style="FONT-SIZE: 10pt; MARGIN: 0px; COLOR: #000000; TEXT-INDENT: 13px; LINE-HEIGHT: 160%; FONT-FAMILY: '바탕'; TEXT-ALIGN: justify"><SPAN style="FONT-SIZE: 10pt; COLOR: #000000; LINE-HEIGHT: 21px; FONT-FAMILY: '바탕'; LETTER-SPACING: 0px; TEXT-ALIGN: justify">그림 6&nbsp; 방사선 조사 감자를 먹였을 때의 체중 변화 추이&nbsp;&nbsp; 106</SPAN> </P><br />
<P style="FONT-SIZE: 10pt; MARGIN: 0px; COLOR: #000000; TEXT-INDENT: 13px; LINE-HEIGHT: 160%; FONT-FAMILY: '바탕'; TEXT-ALIGN: justify"><SPAN style="FONT-SIZE: 10pt; COLOR: #000000; LINE-HEIGHT: 21px; FONT-FAMILY: '바탕'; LETTER-SPACING: 0px; TEXT-ALIGN: justify">그림 7&nbsp; 방사선 조사 감자를 먹였을 때의 체중 변화 추이&nbsp;&nbsp; 106</SPAN> </P><br />
<P style="FONT-SIZE: 10pt; MARGIN: 0px; COLOR: #000000; TEXT-INDENT: 13px; LINE-HEIGHT: 160%; FONT-FAMILY: '바탕'; TEXT-ALIGN: justify"><SPAN style="FONT-SIZE: 10pt; COLOR: #000000; LINE-HEIGHT: 21px; FONT-FAMILY: '바탕'; LETTER-SPACING: 0px; TEXT-ALIGN: justify">그림 8&nbsp; 방사선 조사 감자로 인한 난소 중량의 변화&nbsp;&nbsp; 109</SPAN> </P><br />
<P style="FONT-SIZE: 10pt; MARGIN: 0px; COLOR: #000000; TEXT-INDENT: 13px; LINE-HEIGHT: 160%; FONT-FAMILY: '바탕'; TEXT-ALIGN: justify"><SPAN style="FONT-SIZE: 10pt; COLOR: #000000; LINE-HEIGHT: 21px; FONT-FAMILY: '바탕'; LETTER-SPACING: 0px; TEXT-ALIGN: justify">그림 9&nbsp; 방사선 조사 감자로 인한 사망률&nbsp;&nbsp; 109</SPAN> </P><br />
<P style="FONT-SIZE: 10pt; MARGIN: 0px; COLOR: #000000; TEXT-INDENT: 13px; LINE-HEIGHT: 160%; FONT-FAMILY: '바탕'; TEXT-ALIGN: justify"><SPAN style="FONT-SIZE: 10pt; COLOR: #000000; LINE-HEIGHT: 21px; FONT-FAMILY: '바탕'; LETTER-SPACING: 0px; TEXT-ALIGN: justify">그림 10&nbsp;&nbsp; 방사선 조사 양파로 인한 사망률&nbsp; 111</SPAN><SPAN style="FONT-SIZE: 10pt; COLOR: #000000; LINE-HEIGHT: 21px; FONT-FAMILY: '바탕'; LETTER-SPACING: 0px; TEXT-ALIGN: justify"></SPAN> </P><br />
<P style="FONT-SIZE: 10pt; MARGIN: 0px; COLOR: #000000; TEXT-INDENT: 13px; LINE-HEIGHT: 160%; FONT-FAMILY: '바탕'; TEXT-ALIGN: justify"><SPAN style="FONT-SIZE: 10pt; COLOR: #000000; LINE-HEIGHT: 21px; FONT-FAMILY: '바탕'; LETTER-SPACING: 0px; TEXT-ALIGN: justify">그림 11&nbsp; 방사선 조사 양파로 인한 난소중량과 선량&nbsp;&nbsp; 118</SPAN> </P><br />
<P style="FONT-SIZE: 10pt; MARGIN: 0px; COLOR: #000000; TEXT-INDENT: 13px; LINE-HEIGHT: 160%; FONT-FAMILY: '바탕'; TEXT-ALIGN: justify"><SPAN style="FONT-SIZE: 10pt; COLOR: #000000; LINE-HEIGHT: 21px; FONT-FAMILY: '바탕'; LETTER-SPACING: 0px; TEXT-ALIGN: justify">그림 12&nbsp; 방사선 조사 양파로 인한 고환 중량과 선량&nbsp;&nbsp; 118</SPAN> </P><br />
<P style="FONT-SIZE: 10pt; MARGIN: 0px; COLOR: #000000; TEXT-INDENT: 13px; LINE-HEIGHT: 160%; FONT-FAMILY: '바탕'; TEXT-ALIGN: justify"><SPAN style="FONT-SIZE: 10pt; COLOR: #000000; LINE-HEIGHT: 21px; FONT-FAMILY: '바탕'; LETTER-SPACING: 0px; TEXT-ALIGN: justify">그림 13&nbsp; 방사선 조사 쌀로 인한 사망률(시궁쥐 수컷 30마리)&nbsp; 123</SPAN> </P><br />
<P style="FONT-SIZE: 10pt; MARGIN: 0px; COLOR: #000000; TEXT-INDENT: 13px; LINE-HEIGHT: 160%; FONT-FAMILY: '바탕'; TEXT-ALIGN: justify"><SPAN style="FONT-SIZE: 10pt; COLOR: #000000; LINE-HEIGHT: 21px; FONT-FAMILY: '바탕'; LETTER-SPACING: 0px; TEXT-ALIGN: justify">그림 14&nbsp; 밀감으로 인한 생존률과 종양 발생률(생쥐, 수컷)&nbsp; 138</SPAN> </P><br />
<P style="FONT-SIZE: 10pt; MARGIN: 0px; COLOR: #000000; TEXT-INDENT: 13px; LINE-HEIGHT: 160%; FONT-FAMILY: '바탕'; TEXT-ALIGN: justify"><SPAN style="FONT-SIZE: 10pt; COLOR: #000000; LINE-HEIGHT: 21px; FONT-FAMILY: '바탕'; LETTER-SPACING: 0px; TEXT-ALIGN: justify"><BR></SPAN></P><br />
<P style="FONT-SIZE: 10pt; MARGIN: 0px; COLOR: #000000; TEXT-INDENT: 13px; LINE-HEIGHT: 160%; FONT-FAMILY: '바탕'; TEXT-ALIGN: justify"><SPAN style="FONT-SIZE: 10pt; COLOR: #000000; LINE-HEIGHT: 21px; FONT-FAMILY: '바탕'; LETTER-SPACING: 0px; TEXT-ALIGN: justify">표 1. 세계에서 조사되어 일본으로 수입되고 있을 가능성을 가진 식품군&nbsp;&nbsp; 14</SPAN> </P><br />
<P style="FONT-SIZE: 10pt; MARGIN: 0px; COLOR: #000000; TEXT-INDENT: 13px; LINE-HEIGHT: 160%; FONT-FAMILY: '바탕'; TEXT-ALIGN: justify"><SPAN style="FONT-SIZE: 10pt; COLOR: #000000; LINE-HEIGHT: 21px; FONT-FAMILY: '바탕'; LETTER-SPACING: 0px; TEXT-ALIGN: justify">표 3. 조사한 밀에 의한 사람의 림프구의 염색체 이상&nbsp;&nbsp; 91</SPAN> </P><br />
<P style="FONT-SIZE: 10pt; MARGIN: 0px; COLOR: #000000; TEXT-INDENT: 13px; LINE-HEIGHT: 160%; FONT-FAMILY: '바탕'; TEXT-ALIGN: justify"><SPAN style="FONT-SIZE: 10pt; COLOR: #000000; LINE-HEIGHT: 21px; FONT-FAMILY: '바탕'; LETTER-SPACING: 0px; TEXT-ALIGN: justify">표 4. 조사한 밀에 의한 시궁쥐의 염색체 이상&nbsp;&nbsp; 91</SPAN> </P><br />
<P style="FONT-SIZE: 10pt; MARGIN: 0px; COLOR: #000000; TEXT-INDENT: 13px; LINE-HEIGHT: 160%; FONT-FAMILY: '바탕'; TEXT-ALIGN: justify"><SPAN style="FONT-SIZE: 10pt; COLOR: #000000; LINE-HEIGHT: 21px; FONT-FAMILY: '바탕'; LETTER-SPACING: 0px; TEXT-ALIGN: justify">표 5. 조사한 밀에 의한 생쥐의 염색체 이상&nbsp;&nbsp; 91</SPAN> </P><br />
<P style="FONT-SIZE: 10pt; MARGIN: 0px; COLOR: #000000; TEXT-INDENT: 13px; LINE-HEIGHT: 160%; FONT-FAMILY: '바탕'; TEXT-ALIGN: justify"><SPAN style="FONT-SIZE: 10pt; COLOR: #000000; LINE-HEIGHT: 21px; FONT-FAMILY: '바탕'; LETTER-SPACING: 0px; TEXT-ALIGN: justify">표 6&nbsp; 조사식품과 비조사식품의 아플라톡신 B₁양 생성의 비교&nbsp;&nbsp; 97</SPAN><SPAN style="FONT-SIZE: 10pt; COLOR: #000000; LINE-HEIGHT: 21px; FONT-FAMILY: '바탕'; LETTER-SPACING: 0px; TEXT-ALIGN: justify"></SPAN> </P><br />
<P style="FONT-SIZE: 10pt; MARGIN: 0px; COLOR: #000000; TEXT-INDENT: 13px; LINE-HEIGHT: 160%; FONT-FAMILY: '바탕'; TEXT-ALIGN: justify"><SPAN style="FONT-SIZE: 10pt; COLOR: #000000; LINE-HEIGHT: 21px; FONT-FAMILY: '바탕'; LETTER-SPACING: 0px; TEXT-ALIGN: justify">표 7 소맥에의 조사선량과 아플라톡신 B₁양&nbsp;&nbsp; 97</SPAN> </P><br />
<P style="FONT-SIZE: 10pt; MARGIN: 0px; COLOR: #000000; TEXT-INDENT: 13px; LINE-HEIGHT: 160%; FONT-FAMILY: '바탕'; TEXT-ALIGN: justify"><SPAN style="FONT-SIZE: 10pt; COLOR: #000000; LINE-HEIGHT: 21px; FONT-FAMILY: '바탕'; LETTER-SPACING: 0px; TEXT-ALIGN: justify">표 8 조사처리식품명과 그 조사선량&nbsp;&nbsp; 99</SPAN> </P><br />
<P style="FONT-SIZE: 10pt; MARGIN: 0px; COLOR: #000000; TEXT-INDENT: 13px; LINE-HEIGHT: 160%; FONT-FAMILY: '바탕'; TEXT-ALIGN: justify"><SPAN style="FONT-SIZE: 10pt; COLOR: #000000; LINE-HEIGHT: 21px; FONT-FAMILY: '바탕'; LETTER-SPACING: 0px; TEXT-ALIGN: justify">표 9 조사식품의 보존기간&nbsp;&nbsp; 99</SPAN><SPAN style="FONT-SIZE: 10pt; COLOR: #000000; LINE-HEIGHT: 21px; FONT-FAMILY: '바탕'; LETTER-SPACING: 0px; TEXT-ALIGN: justify"></SPAN> </P><br />
<P style="FONT-SIZE: 10pt; MARGIN: 0px; COLOR: #000000; TEXT-INDENT: 13px; LINE-HEIGHT: 160%; FONT-FAMILY: '바탕'; TEXT-ALIGN: justify"><SPAN style="FONT-SIZE: 10pt; COLOR: #000000; LINE-HEIGHT: 21px; FONT-FAMILY: '바탕'; LETTER-SPACING: 0px; TEXT-ALIGN: justify">표 11&nbsp; 2대째의 새끼의 기형발생률(생쥐)&nbsp;&nbsp; 119</SPAN> </P></p>
]]></content:encoded>
			<wfw:commentRss>http://www.chsc.or.kr/?post_type=reference&#038;p=1868/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>[광우병] 한-캐나다 WTO 분쟁 상황 정리 (WTO 원문 자료)</title>
		<link>http://www.chsc.or.kr/?post_type=reference&#038;p=1446</link>
		<comments>http://www.chsc.or.kr/?post_type=reference&#038;p=1446#comments</comments>
		<pubDate>Thu, 26 Nov 2009 09:56:20 +0000</pubDate>
		<dc:creator>건강과대안</dc:creator>
				<category><![CDATA[광우병]]></category>
		<category><![CDATA[식품 · 의약품]]></category>
		<category><![CDATA[EU]]></category>
		<category><![CDATA[WTO 분쟁해결기구]]></category>
		<category><![CDATA[대만]]></category>
		<category><![CDATA[미국]]></category>
		<category><![CDATA[일본]]></category>
		<category><![CDATA[제3자국 참여]]></category>
		<category><![CDATA[캐나다산 쇠고기]]></category>
		<category><![CDATA[패널 설치]]></category>

		<guid isPermaLink="false">http://www.chsc.or.kr/?post_type=reference&#038;p=1446</guid>
		<description><![CDATA[캐나다는 2009년 4월 9일 자국산 쇠고기에 대한 한국의 수입금지조치 등이 WTO 협정에 위반된다는 사유로 한국을 WTO에 제소했습니다. 4월 28일 EU도 제소에 참여할 것을 요청했습니다.&#160;5월 7일 한국과 캐나다는 WTO [...]]]></description>
				<content:encoded><![CDATA[<p><P>캐나다는 2009년 4월 9일 자국산 쇠고기에 대한 한국의 수입금지조치 등이 WTO 협정에 위반된다는 사유로 한국을 WTO에 제소했습니다. 4월 28일 EU도 제소에 참여할 것을 요청했습니다.<BR>&nbsp;<BR>5월 7일 한국과 캐나다는 WTO 양자협의를 개최하였으나 상호 원칙적인 입장만 확인하였습니다. 통상 분쟁 사안이 WTO에 제소되면 양 당사국은 1단계로 60일간 협의를 진행하도록 되어 있습니다. 이 기간동안 한-캐나다는 단 1회의 공식 협의를 했을 뿐이고, 비공개 협의는 계속 해왔던 것으로 보입니다.<BR>&nbsp;<BR>7월 20일, 캐나다에서 WTO 분쟁해결기구에 패널 설치를 요청하였고, 한국은 이를 거부하였습니다. 그러나 8월 20일 캐나다측의 2차 패널 설치 요청으로 8월 31일 패널이 설치되었습니다. 분쟁해소패널 절차가 진행 중이더라도 양자가 합의점을 찾으면 언제든 분쟁은 종료됩니다. <BR>&nbsp;<BR>11월 13일 마가렛 리앙을 주심으로 마디디아 프란케, 구드문두르 헬케이슨을 위원으로 하는 3인 패널이 설치되었습니다. (Chairperson: Ms Margaret Liang / Members: Mr Mathias Francke , Mr Gudmundur Helgason )<BR>&nbsp;<BR>11월 16일 아르헨티나, 브라질, 인도, 중국, 유럽연합(EU), 일본, 대만, 미국 등 8개국이 제3자국 자격으로 분쟁해소패널 절차에 참여하는 권리를 부여받았습니다.(9월 22일, 농식품부 발표에 따르면 이들 8개국은 이미 제3자국 참여의사를 분쟁해소패널에 밝혔다고 합니다.)<BR><BR>8개국 중에서 아르헨티나, 브라질, 인도, 중국, 유럽연합, 미국은 수출국 입장에서 참여한 것이고 일본과 대만은 수입국 입장에서 참여한 것입니다. 한-캐나다 분쟁해결기구의 패널 판정 결과에 따라 아르헨티나, 브라질, 인도, 중국, 유럽연합산 쇠고기 수입이 불가피해지는 상황이 발생할 수 있으며, 미국산 쇠고기 수입조건 중에서 2008년 촛불시위의 성과에 의해 &#8216;잠정적으로 30개월 미만&#8217;만 수입하기로 한 조치가 무력화될 가능성도 있을 뿐만 아니라, 20개월 미만만 수입하고 있는 일본의 수입기준에 악영향을 끼칠 수도 있고, 2009년 대만의 시위와 반대여론에 의해 &#8216;잠정적으로 30개월 미만&#8217;만 수입하고 민간업자들의 자율결의에 의해 &#8216;내장&#8217;을 수입하지 않기로 한 대만의 수입기준에도 악영향을 끼칠 수도 있습니다. 그러므로 제3자국으로 참여한 국가들은 모두 쇠고기에 관한 첨예한 이해관계가 있습니다.<BR><BR>================================<BR><BR>DISPUTE SETTLEMENT: DISPUTE DS391 </P><br />
<P>출처 : <A href="http://www.wto.org/english/tratop_e/dispu_e/cases_e/ds391_e.htm">http://www.wto.org/english/tratop_e/dispu_e/cases_e/ds391_e.htm</A> </P><br />
<P>Korea — Measures Affecting the Importation of Bovine Meat and Meat Products from Canada </P><br />
<P>(1) WORLD TRADE ORGANIZATION </P><br />
<P>WT/DS391/1 <BR>G/L/883 <BR>G/SPS/GEN/918 </P><br />
<P>15 April 2009 <BR>(09-1771) </P><br />
<P>Original: English </P><br />
<P>KOREA &#8211; MEASURES AFFECTING THE IMPORTATION OF BOVINE MEAT AND MEAT PRODUCTS FROM CANADA </P><br />
<P>Request for Consultations by Canada </P><br />
<P>The following communication, dated 9 April 2009, from the delegation of Canada to the delegation of Korea and to the Chairman of the Dispute Settlement Body, is circulated in accordance with Article 4.4 of the DSU. <BR>______________ </P><br />
<P>The Government of Canada hereby requests consultations with the Republic of Korea (Korea) pursuant to Articles 1 and 4 of the Understanding on Rules and Procedures Governing the Settlement of Disputes, Article XXII of the General Agreement on Tariffs and Trade 1994 (GATT 1994) and Article 11 of the Agreement on the Application of Sanitary and Phytosanitary Measures (SPS Agreement), concerning measures affecting the importation of bovine meat and meat products from Canada. </P><br />
<P>The measures at issue include, but are not limited to, the following: </P><br />
<P>- Administrative Order No. 51584-476, which entered into force on 21 May 2003; </P><br />
<P>- Korean Act No. 9130 amending the Act on the Prevention of Contagious Animal Diseases (also known as the Livestock Epidemic Prevention Act), which entered into force on 11 September 2008. </P><br />
<P>For each of the measures referred to above, this request also covers any amendments, replacements, extensions, implementing measures or other related measures. </P><br />
<P>These measures adversely affect the importation of bovine meat and meat products from Canada. Administrative Order No. 51584-476 prohibits the importation into Korea of bovine meat and meat products from Canada allegedly to protect against risks arising from bovine spongiform encephalopathy (BSE). Korean Act No. 9130 amending the Act on the Prevention of Contagious Animal Diseases sets out a number of new stringent conditions for lifting the import ban, including subjecting any import health requirements for the importation of Canadian bovine meat and meat products to the approval of the Korean National Assembly. </P><br />
<P>Canada is of the view that these measures are inconsistent with the obligations of Korea under the SPS Agreement and the GATT 1994. The provisions of these Agreements with which the measures appear to be inconsistent include the following: </P><br />
<P>* Articles 2.2, 2.3, 3.1, 3.3, 5.1, 5.5, 5.6, 5.7, 6.1, 8 and Annex C of the SPS Agreement; and </P><br />
<P>* Articles I:1, III:4 and XI:1 of the GATT 1994. </P><br />
<P>Canada reserves the right to raise additional claims and legal matters regarding the measures at issue during the course of consultations. </P><br />
<P>Canada looks forward to receiving the reply of Korea to this request and welcomes any suggestions that it might wish to make concerning the date on which these consultations could take place and the location of the consultations. </P><br />
<P>(2) WORLD TRADE ORGANIZATION </P><br />
<P>WT/DS391/2 </P><br />
<P>28 April 2009 <BR>(09-2025) </P><br />
<P>Original: English </P><br />
<P>KOREA &#8211; MEASURES AFFECTING THE IMPORTATION OF BOVINE MEAT AND MEAT PRODUCTS FROM CANADA </P><br />
<P>Request to Join Consultations </P><br />
<P>Communication from the European Communities </P><br />
<P>The following communication, dated 23 April 2009, from the delegation of the European Communities to the delegation of Korea, the delegation of Canada and to the Chairman of the Dispute Settlement Body, is circulated in accordance with Article 4.11 of the DSU. <BR>_______________ </P><br />
<P>Pursuant to Article 4.11 of the Understanding on Rules and Procedures Governing the Settlement of Disputes (DSU), the European Communities hereby notifies the Government of Korea, the Government of Canada and the Dispute Settlement Body that the European Communities wishes to be joined in the consultations requested by Canada in a communication circulated to WTO Members on 15 April 2009 (WT/DS391/1 G/L/883,G/SPS/GEN/918) entitled Korea &#8211; Measures Affecting the Importation of Bovine Meat and Meat Products from Canada. </P><br />
<P>The European Communities&#8217; position as an exporter of bovine meat and meat products makes its trade interest in the present dispute substantial. </P><br />
<P>The European Communities looks forward to being informed of the date and venue of the consultations. </P><br />
<P>(3) WORLD TRADE ORGANIZATION </P><br />
<P>WT/DS391/3 </P><br />
<P>10 July 2009 <BR>(09-3375) </P><br />
<P>Original: English </P><br />
<P>KOREA &#8211; MEASURES AFFECTING THE IMPORTATION OF BOVINE MEAT AND MEAT PRODUCTS FROM CANADA </P><br />
<P>Request for the Establishment of a Panel by Canada </P><br />
<P>The following communication, dated 9 July 2009, from the delegation of Canada to the Chairman of the Dispute Settlement Body, is circulated pursuant to Article 6.2 of the DSU. <BR>_______________ </P><br />
<P>On 9 April 2009, the Government of Canada requested consultations with the Republic of Korea (&#8220;Korea&#8221;) concerning measures affecting the importation of bovine meat and meat products from Canada, pursuant to Articles 1 and 4 of the Understanding on Rules and Procedures Governing the Settlement of Disputes (&#8220;DSU&#8221;), Article XXII of the General Agreement on Tariffs and Trade 1994 (&#8220;GATT 1994&#8243;) and Article 11 of the Agreement on the Application of Sanitary and Phytosanitary Measures (&#8220;SPS Agreement&#8221;). </P><br />
<P>On 7 May 2009, consultations were held in Geneva, with a view to reaching a satisfactory resolution of the matter. Unfortunately, the consultations failed to settle the dispute. </P><br />
<P>Canada therefore requests the DSB to establish a panel to examine this matter with standard terms of reference, as set out in Article 7.1 of the DSU, pursuant to Articles 4 and 6 of the DSU, Article XXII of the GATT 1994 and Article 11 of the SPS Agreement. </P><br />
<P>Korea maintains a ban on the importation of bovine meat and meat products from Canada allegedly to protect against risks arising from bovine spongiform encephalopathy (BSE). </P><br />
<P>In addition, Korea has adopted measures that place unjustified restrictions on the resumption of imports of bovine meat and meat products from Canada. For instance: </P><br />
<P>(i) Korea prohibits the importation of all beef and beef products derived from cattle 30 months of age and over that originate from countries where there has been a case of BSE in the last five years; </P><br />
<P>(ii) Korea makes the import health requirements necessary for the lifting of the ban on bovine meat and meat products from Canada subject to the deliberation of its National Assembly; </P><br />
<P>(iii) In the event that the ban on bovine meat and meat products from Canada were lifted, Korea may re-impose a ban on imports of all bovine meat and meat products from Canada indefinitely were an additional case of BSE to occur in Canada. </P><br />
<P>Moreover, Korea&#8217;s measures discriminate between Canada and other WTO Members. </P><br />
<P>The measures covered in this panel request are the following: </P><br />
<P>- Act on the Prevention of Contagious Animal Diseases (Law No. 907), which entered into force on 30 December 1961, as amended, including by Korean Act No. 9130, which entered into force on 11 September 2008; </P><br />
<P>- Enforcement Regulations of the Act on the Prevention of Livestock Epidemics, as amended, including by Decree No. 68 of the Minister of Food, Agriculture, Forestry and Fisheries, dated 30 April 2009; </P><br />
<P>- Notice No. 1998-76 of the Minister of Agriculture and Forestry (Animal Health Requirements for the importation of Canadian cloven-hoofed animals and their products into the Republic of Korea), dated 7 December 1998; </P><br />
<P>- Administrative Order No. 51584-476, dated 21 May 2003; </P><br />
<P>- Notice No. 2004-23 of the Minister of Agriculture (Prohibited Countries as Exporters of Designated Inspectable Articles), dated 3 May 2004, as amended, including by Notice No. 2009-5 of the Minister of Food, Agriculture, Forestry and Fisheries (Partial Amendment of the Clauses Applicable to the Prohibited DIA Exporting Countries), dated 17 February 2009; </P><br />
<P>- Notice 2008-74 of the Minister of Food, Agriculture, Forestry and Fisheries (Method of Import Risk Analysis Concerning Import of Designated Inspectable Articles), dated 20 August 2008; </P><br />
<P>- Notice No. 2008-15 of the Minister of Food, Agriculture, Forestry and Fisheries (Import Health Requirements for U.S. Beef and Beef Products), dated 26 June 2008; and </P><br />
<P>- Any amendments or extensions to the above, or implementing measures on which Korea may rely on in imposing a prohibition on the importation of bovine meat and meat products from Canada or in placing further restrictions on the resumption of imports of bovine meat and meat products from Canada. </P><br />
<P>Each of these measures is inconsistent with the obligations of Korea under the SPS Agreement. In particular, Canada considers that each of these measures is inconsistent with the following provisions: </P><br />
<P>1. Article 2.2 of the SPS Agreement because they are not applied only to the extent necessary to protect human or animal life or health, they are not based on scientific principles and they are maintained without sufficient scientific evidence. </P><br />
<P>2. Article 2.3 of the SPS Agreement because they arbitrarily or unjustifiably discriminate between Members where identical or similar conditions prevail and they are applied in a manner that constitutes a disguised restriction on international trade. </P><br />
<P>3. Article 3.1 of the SPS Agreement because they are not based on international standards, guidelines or recommendations. </P><br />
<P>4. Article 3.3 of the SPS Agreement because they result in a higher level of sanitary protection than would be achieved by measures based on the relevant international standards, guidelines or recommendations, in the absence of a scientific justification or of a determination by Korea of its appropriate level of sanitary protection in accordance with the relevant provisions of paragraphs 1 through 8 of Article 5. </P><br />
<P>5. Article 5.1 of the SPS Agreement because they are not based on an assessment, as appropriate to the circumstances, of the risks to human or animal life or health, taking into account risk assessment techniques developed by relevant international organizations. </P><br />
<P>6. Article 5.5 of the SPS Agreement because Korea maintains arbitrary or unjustifiable distinctions in the levels of sanitary protection that it considers appropriate in different situations and those distinctions result in discrimination or a disguised restriction on international trade. </P><br />
<P>7. Article 5.6 of the SPS Agreement because they are more trade-restrictive than required to achieve Korea&#8217;s appropriate level of sanitary protection. </P><br />
<P>8. Article 8 and Annex C(1)(a), first clause, because they cannot be undertaken and completed without undue delay. </P><br />
<P>9. Were Korea to invoke Article 5.7 of the SPS Agreement in justification of its measures, they do not meet the requirements necessary to allow for their provisional adoption and/or maintenance under that Article. </P><br />
<P>Canada also considers that each of these measures is inconsistent with the following provisions of the GATT 1994: </P><br />
<P>1. Article I:1 of the GATT 1994 because Korea does not accord the same treatment it grants to bovine meat and meat products originating in certain countries to the like products originating in Canada. </P><br />
<P>2. Article III:4 of the GATT 1994 because they result in less favourable treatment for imported bovine meat and meat product than for domestic bovine meat and meat products. </P><br />
<P>3. Article XI:1 of the GATT 1994 because they constitute prohibitions or restrictions on importation. </P><br />
<P>Canada asks that this request be placed on the agenda of the next meeting of the DSB, scheduled to be held on 20 July 2009. </P><br />
<P>(4) WORLD TRADE ORGANIZATION </P><br />
<P>WT/DS391/4 </P><br />
<P>16 November 2009 <BR>(09-5671) </P><br />
<P>KOREA &#8211; MEASURES AFFECTING THE IMPORTATION OF BOVINE MEAT AND MEAT PRODUCTS FROM CANADA </P><br />
<P>Constitution of the Panel Established at the Request of Canada </P><br />
<P>Note by the Secretariat </P><br />
<P>1. At its meeting on 31 August 2009, the Dispute Settlement Body (DSB) established a panel pursuant to the request of Canada in document WT/DS391/3, in accordance with Article 6 of the Dispute Settlement Understanding (DSU) (WT/DSB/M/273). </P><br />
<P>2. The Panel&#8217;s terms of reference are the following: </P><br />
<P>&#8220;To examine, in the light of the relevant provisions of the covered agreements cited by the parties to the dispute, the matter referred to the DSB by Canada in document WT/DS391/3 and to make such findings as will assist the DSB in making the recommendations or in giving the rulings provided for in those agreements.&#8221; </P><br />
<P>3. On 4 November 2009, Canada requested the Director-General to determine the composition of the panel, pursuant to paragraph 7 of Article 8 of the DSU. This paragraph provides: </P><br />
<P>&#8220;If there is no agreement on the panelists within 20 days after the date of the establishment of a panel, at the request of either party, the Director-General, in consultation with the Chairman of the DSB and the Chairman of the relevant Council or Committee, shall determine the composition of the panel by appointing the panelists whom the Director-General considers most appropriate in accordance with any relevant special or additional rules or procedures of the covered agreement or covered agreements which are at issue in the dispute, after consulting with the parties to the dispute. The Chairman of the DSB shall inform the Members of the composition of the panel thus formed no later than 10 days after the date the Chairman receives such a request.&#8221; </P><br />
<P>4. On 13 November 2009, the Director-General accordingly composed the Panel as follows: </P><br />
<P>Chairperson: Ms Margaret Liang </P><br />
<P>Members: Mr Mathias Francke </P><br />
<P>Mr Gudmundur Helgason </P><br />
<P>5. Argentina, Brazil, India, China, the European Communities, Japan, Chinese Taipei and the United States have reserved their rights to participate in the Panel proceedings as third parties.</P></p>
]]></content:encoded>
			<wfw:commentRss>http://www.chsc.or.kr/?post_type=reference&#038;p=1446/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>[GMO] EU농업장관, 몬산토사 GM 옥수수 신품종 승인 거부</title>
		<link>http://www.chsc.or.kr/?post_type=reference&#038;p=1190</link>
		<comments>http://www.chsc.or.kr/?post_type=reference&#038;p=1190#comments</comments>
		<pubDate>Tue, 20 Oct 2009 19:09:33 +0000</pubDate>
		<dc:creator>건강과대안</dc:creator>
				<category><![CDATA[GMO]]></category>
		<category><![CDATA[식품 · 의약품]]></category>
		<category><![CDATA[EU]]></category>
		<category><![CDATA[GM 옥수수]]></category>
		<category><![CDATA[몬산토]]></category>
		<category><![CDATA[미국]]></category>
		<category><![CDATA[유전자조작]]></category>
		<category><![CDATA[유전자조작 옥수수]]></category>

		<guid isPermaLink="false">http://www.chsc.or.kr/?post_type=reference&#038;p=1190</guid>
		<description><![CDATA[EU farm ministers refuse to okay new GM maize strains출처 : (AFP) Mon&#160;Oct&#160;19, 2:02&#160;pm&#160;ET LUXEMBOURG (AFP) – European Union farm ministers refused to give their seal of approval [...]]]></description>
				<content:encoded><![CDATA[<p><FONT size=5>EU farm ministers refuse to okay new GM maize strains</FONT><BR><BR>출처 : (AFP) Mon&nbsp;Oct&nbsp;19, 2:02&nbsp;pm&nbsp;ET</ABBR><!-- end .byline --><br />
<DIV class=yn-story-content><br />
<P>LUXEMBOURG (AFP) – <SPAN class=yshortcuts id=lw_1255976118_0>European Union farm</SPAN> ministers refused to give their seal of approval on Monday to plans to allow the import of genetically-modified maize from US growers, diplomats said.</P><br />
<P>During a meeting of <SPAN class=yshortcuts id=lw_1255976118_1>European Union agriculture ministers</SPAN> in <SPAN class=yshortcuts id=lw_1255976118_2 style="CURSOR: hand; BORDER-BOTTOM: #0066cc 1px dashed">Luxembourg</SPAN> dominated by crisis in the dairy sector, nations were unable to agree on proposals to greenlight the latest batch of so-called &#8216;Frankenstein foods.&#8217;</P><br />
<P><SPAN class=yshortcuts id=lw_1255976118_3 style="CURSOR: hand; BORDER-BOTTOM: #0066cc 1px dashed">Agriculture Commissioner Mariann Fischer Boel</SPAN> sought the go-ahead for two strains of corn produced by Monsanto and another by rivals Pioneer to be cleared for import by European firms.</P><br />
<P>Several sources told AFP that the decision would ultimately be left up to the commission itself, because if no agreement can be reached by the ministers Brussels will have free rein to choose.</P><br />
<P>Fischer Boel argued that a shortage of soya for animal feedstuffs and over-reliance on US exporters meant the EU had to get over old fears about new products.</P><br />
<P>She slammed regulations that meant one large shipment of soya was turned back from EU borders this summer because traces of unauthorised GM maize, that she said were harmless, were found in its containers.</P><br />
<P>&#8220;We have to rely on science and not on emotions,&#8221; said Fischer Boel. &#8220;The commission will take a clear decision and that will be a yes,&#8221; she vowed.</P><br />
<P>Only a handful of genetically modified crops have been approved for cultivation in the <SPAN class=yshortcuts id=lw_1255976118_4 style="CURSOR: hand; BORDER-BOTTOM: #0066cc 1px dashed">European Union</SPAN>, but of them only Monsanto&#8217;s MON810 maize, approved in 1998, is so far being grown.</P><br />
<P>The MON810 case has become a source of transatlantic friction. The United States has warned <SPAN class=yshortcuts id=lw_1255976118_5>Europe</SPAN> against using environmental issues as an excuse for protectionism.</P><br />
<P>Six <SPAN class=yshortcuts id=lw_1255976118_6>European countries</SPAN> &#8212; <SPAN class=yshortcuts id=lw_1255976118_7>Austria</SPAN>, France, Germany, Greece, <SPAN class=yshortcuts id=lw_1255976118_8>Hungary</SPAN> and Luxembourg &#8212; had adopted safeguard clauses to ban its cultivation on their territory.</P><br />
<P></P></DIV></p>
]]></content:encoded>
			<wfw:commentRss>http://www.chsc.or.kr/?post_type=reference&#038;p=1190/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
